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ABSTRACT 
Hypoplastic Left Heart Syndrome (HLHS) is a congenital heart disease where the left 
ventricle and ascending aorta are underdeveloped. The first of three palliative surgeries 
for this malformation is the Norwood procedure. In this surgery, an opening is made 
between the left and right atrium so that all blood can flow into the right ventricle (RV). 
A reconstructed aorta is anastomosed (connected) to the RV so that the RV can pump 
oxygenated blood to the body (the systemic circulation). To divert part of the systemic 
blood flow to the pulmonary circulation, the modified Blalock-Taussig Shunt (mBTS) is 
connected from the innominate artery to the pulmonary artery. However, Norwood 
patients with an mBTS may experience retrograde flow from the coronary circulation 
(which supplies blood to the heart) to the pulmonary circulation via the mBTS. This 
shunt steal of coronary blood can lead to detrimental issues such as myocardial ischemia 
leading to right ventricular dysfunction.  
In this study, a multi-scale model of the Norwood procedure couples a three-
dimensional (3D) test section of the reconstructed aortic arch with a lumped parameter 
network (LPN) describing the Norwood patient’s global hemodynamics. Previously, only 
in silico multi-scale models of the Norwood circulation have modeled the coronary 
circulation and the effects of varying mBTS sizes on coronary perfusion. Here, a novel in 
vitro coronary circulation model is adapted from such in silico studies and implemented 
into a previously validated in vitro mock circulatory system (MCS) of the Norwood with 
mBTS palliation. The MCS was verified against an analytical model and validated using 
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a patient-specific test section and data. A parametric test in which the size of the mBTS 
inner diameter was varied from 3mm to 4mm was performed. The results showed that 
increasing mBTS size results in decreased diastolic aortic pressure, which decreases 
coronary blood flow (CBF) during diastole.  
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CHAPTER ONE 
THE NORWOOD PROCEDURE AND CORONARY CIRCULATION  
Hypoplastic Left Heart Syndrome 
Every year there are approximately 10 in 10,000 children born with Hypoplastic Left 
Heart Syndrome [1]. Although rare, this congenital disease is one of the deadliest and 
attributes to 20% of the heart-related deaths in newborns per year [1]. The HLHS 
physiology is marked by a severely underdeveloped left ventricle (LV) and aorta that are 
unable to support the systemic circulation: the blood flow that provides oxygen to the 
body. Other characteristics of this disease may include aortic valve or mitral valve 
stenosis [2]: narrowing that further hinders the blood flow through the left side of the 
heart. A full anatomical representation of the HLHS heart relative to a normal healthy 
heart can be seen in Figure 1.1.  
 
Figure 1.1 Anatomy of a normal heart (Left) and a heart with HLHS (Right). [3] 
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 As seen in Figure 1.1, the hypoplastic LV’s size greatly limits its ability to 
provide oxygenated blood to the systemic circulation. At birth, the patent ductus 
arteriosus (PDA) connects the pulmonary artery to the aortic arch, providing oxygenated 
blood to the systemic circulation. However, the PDA will close within a few weeks after 
birth and, unless medically intervened, the disease is fatal [4]. Symptoms of HLHS 
include fatigue or cyanosis: where the patient’s skin tone appears blue, a mark of oxygen 
insufficiency [4]. This alerts doctors to perform medical imaging techniques such as 
echocardiography, and from there HLHS can be diagnosed. Once diagnosed, 
reconstruction of the heart is performed within 2-5 days of the patient’s life. [4] 
HLHS patients are treated with a set of 3 palliative surgeries: the Norwood, 
Glenn, and Fontan. The Norwood procedure (Stage 1) and its many variations occur 
within the first few days of birth. The Glenn procedure (Stage 2) occurs within 4-6 
months. The previous surgeries are all performed with the end goal to create the Fontan 
circulation, marked by the total cavo-pulmonary connection [5]. This is the Fontan 
procedure (Stage 3) and occurs when the patient is 2-6 years old [4]. Overall, the survival 
rate to adulthood for these patients is limited, particularly with 5-30% mortality after 
Stage 1 [4, 6]. Due to these high rates, the Norwood procedure continues to be a topic of 
research in hopes of discovering new methods or optimizing the current palliative 
method. 
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Stage 1 Anatomy and Physiology 
 The purpose of the Norwood procedure is to provide both systemic and 
pulmonary blood flow [7]. To do this, a neo-aorta is constructed using the hypoplastic 
ascending aorta and a homograft patch, and anastomosed (connected) to the pulmonary 
trunk. The native aortic trunk may then be anastomosed to the neo-aorta by means of the 
Damus-Kaye-Stansel (DKS) procedure. In this configuration, the RV now acts as the 
systemic ventricle and pumps blood into the neo-aorta to the systemic circulations: upper 
body, lower body, and coronary circulations. The RV receives both oxygenated and 
deoxygenated blood from the right atrium (RA) and the left atrium (LA) via the atrial 
septal defect: an opening between the RA and LA.  
The trademark of Stage 1 is the means by which it diverts part of the blood flow 
back to the pulmonary arteries (PA) to be oxygenated in the lungs. This is achieved using 
a shunt such as the modified Blalock-Taussig shunt (mBTS). Figure 1.2 shows the Stage 
1 with mBTS palliation of a HLHS heart. 
 
Figure 1.2 Anatomy of the Stage 1 with mBTS palliation for HLHS. [3] 
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 The mBTS is a polytetrafluorethylene conduit from the innominate artery 
(INOM) or subclavian artery to the left or right PA [6]. When blood is pumped from the 
RV, it travels up through the aorta into the systemic arteries, including the INOM. As 
blood passes through the INOM, it can then pass through the mBTS to the PA. This 
completes the parallel systemic and pulmonary circulation [7] of the Norwood 
physiology, which is in contrast to a series circulation for a normal patient.  
From Figure 1.2, it can be seen that the RV is the main pumping mechanism for 
the Norwood heart. It provides the flow of blood into the ascending aorta, the cardiac 
output (CO), which is used to perfuse both the systemic and pulmonary circulations.  As 
indicated by Figure 1.2, the CO is mixed with both oxygen-rich and oxygen-poor blood. 
Placement and size of the mBTS is chosen in order to provide a proper balance of 
pulmonary-to-systemic blood flow (QP/QS) [8]. This is necessary to ensure that correct 
blood-oxygen saturation rates are met.  
The mBTS’s performance is highly dependent on the pulmonary vascular 
resistance (PVR), which is much smaller relative to the systemic vascular resistance 
(SVR), and changes with patient growth [9]. In vitro studies have found that a ratio of 
about 1:1 for Qp/QS using a mBTS with a diameter of 3.5 mm is optimal for systemic 
oxygenation [8-9]. While achieving this balance is possible, the mBTS is still marked by 
complications. Most notably, the mBTS has been associated with “shunt steal”: diastolic 
flow into the mBTS from retrograde flow in the systemic arteries [10]. In particular, this 
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diastolic runoff into the pulmonary circulation has been associated with detriment to the 
flow of blood in the coronary circulation. [6, 10–12]  
 Coronary Arteries for the Healthy Heart 
 The heart can be thought of as a pump whose energy source is oxygenated blood 
traveling through the coronary circulation. In a healthy heart, the coronary circulation is 
composed of coronary arteries that originate at the two ostia located in the aortic sinuses 
behind the aortic valve, as seen in Figure 1.3 below. From there, the left (LCA) and right 
(RCA) coronary arteries spread over the outer epicardium and descend into the inner 
myocardium and innermost endocardium of the left and right ventricles, respectively. 
This blood flow provides the oxygen the heart muscle needs for contraction during 
systole. The deoxygenated blood is then directed through coronary veins that empty into 
the RA. [13]  
 
Figure 1.3 Anatomy of a normal heart detailing the location of the coronary arteries. [14] 
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 Total coronary blood flow (QCOR or CBF) is said to be about 4% of the CO and 
predominantly occurs during diastole [15]. This time dependent flow is related to the 
interaction of the systemic ventricle and myocardium with the coronary vessels [13]. 
During systole, the ventricle contracts and increases the intramyocardial tissue pressure 
[16], squeezing the coronary vessels and increasing their resistance to arterial coronary 
blood flow (CBF). Additionally, the forward-moving cardiac output opens the aortic 
valve and the valve leaflets form a barrier between the coronary ostia and the flow 
(Figure 1.4). 
 
Figure 1.4 The aortic valve leaflet position during (A) systole and (B) diastole. Arrows show 
blood flow direction [17]. 
 
As seen in Figure 1.4, it is during diastole that the aortic sinuses fill and the coronary 
arteries receive blood. When the aortic valve closes, it is the start of ventricular 
isovolumetric relaxation and diastole. Here the coronary vessels are least subjected to the 
intramyocardial pressure from ventricular movement and have the greatest coronary 
perfusion pressure (CPP): the difference between diastolic aortic pressure and atrial 
pressure. And so, this is where CBF is at its maximum [18]. Then as the diastolic aortic 
pressure decreases through the end of the cardiac cycle, the CPP decreases and CBF 
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responds similarly. This agrees with the echocardiograms (echos) of coronary flow 
velocities seen in Figure 1.5, where the majority of flow is during diastole. 
 
Figure 1.5 Echos of coronary flow of the left anterior descending coronary artery for a (Left)  
post-aortic-valve replacement patient [19] and (Right) a normal heart [20]. S and D represent systole 
and diastole, respectively.  
 
In Figure 1.5, the differences between flow in systole versus diastole are quite distinct 
for both images. The image on the left is from the Left Anterior Descending artery for a 
patient who had undergone aortic valve replacement surgery, while the image on the right 
is from the same artery of a healthy human’s heart. It is apparent that the heart receives 
blood, and thus oxygen, during its relaxed stage of diastole – the supply. It is also clear 
that during systole, when the heart is exerting itself and in need of energy, it is not 
receiving as much flow – the demand. This supply-demand relationship can be further 
understood by the Myocardial Oxygen Supply-Demand Balance (MOB) [18]. 
 The MOB dictates the coronary vasomotor tone’s response. This results in 
vasodilation or vasoconstriction of the coronary vessels to allow for increased or 
decreased CBF, respectively [21]. The MOB relates the ratio of the amount of CBF the 
heart needs versus the amount of CBF supplied. Factors affecting the supply of oxygen to 
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the heart include heart rate (HR), CPP, blood oxygen content, and the diameter of the 
coronary artery [18]. The demand of oxygen is also governed by HR, preload and 
afterload on the ventricle, and myocardial inotropy [18]. Thus, the more forcefully and 
longer the ventricle must contract in systole, the more it will demand oxygen. Likewise, 
the longer the ventricle is relaxed in diastole or the more pronounced the diastolic aortic 
pressure, the greater the supply of oxygen to the myocardium. A quantitative 
measurement of the MOB is made through the Endocardial Viability Ratio (EVR) [21].  
The EVR is the ratio of the Diastolic Pressure Time Index (DPTI) to the Tension 
Time Index (TTI) [21]. The DPTI is the “product of the coronary perfusion pressure and 
diastolic time,” while the TTI is the “product of systolic pressure and systolic time” [21]. 
In healthy circumstances, the EVR value is 1 or greater, meaning that the oxygen supply 
meets or exceeds the demand. However, an EVR below 0.7 typically signifies ischaemic 
conditions [21], meaning the heart tissue is not properly oxygenated for the amount of 
work it is performing. In these conditions, the blood flow to the coronary circulation is 
being obstructed. It is important to note that the rate of myocardial oxygen extraction 
does not increase as substantially as myocardial oxygen demand [16]. Furthermore, an 
increase in oxygen supply to overcome a low EVR can only be met by an increase in 
CBF [15]. And so, any deterrent of coronary blood flow will be to the detriment of the 
heart. Unfortunately, such a deterrent exists in the Stage 1 physiology. 
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Coronary Arteries in Norwood Physiology 
 During Stage 1 procedure, some surgeons prefer to not transplant the fragile coronary 
arteries to the neo-aorta [22]. Instead, as mentioned above, they perform the DKS 
procedure [23]. In this method, the native aortic root is anastomosed to the neo-aorta, 
allowing for blood flow from the RV up through the neo-aorta to descend into the native 
aorta and perfuse the coronaries. In this configuration, the coronary arteries are allowed 
to maintain their native origin.  
Studies have shown that the size of the coronary arteries and ostia between HLHS 
patients and those of normal conditions do not differ [24]. However, according to 
Donnelly et al, Norwood patients are said to have “less [coronary] perfusion and oxygen 
delivery to the systemic ventricle” [12]. Donnelly further mentioned that the hypoplastic 
LV might even steal from the RV, which is performing an additional workload as it 
supports both systemic and pulmonary circulations.  
In an in vivo study of patients after the Norwood surgery, Charpie et al. found that 
patients requiring medical intervention for decreased ventricular function correlated with 
having higher QP/QS ratios and less systemic oxygen delivery than patients who did not 
need medical intervention [25]. The choice of mBTS, particularly its size, is used to 
control the QP/QS ratio. These results reveal the sensitivity that myocardial function has 
to the mBTS. These findings have been further expressed in other studies that say, when 
compared to other Stage 1 shunting options, the mBTS has the more devastating effects 
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on coronary perfusion [8, 10, 11]. These particular effects of the mBTS are referred to as 
“shunt steal” of the coronary blood flow [10]. 
Shunt steal of the CBF occurs when the mBTS, which is an open channel throughout 
the cardiac cycle, “steals” blood that would typically flow towards the coronary 
circulation. The diastolic aortic pressure, which would normally help perfuse the 
coronaries, instead directs the flow towards the pulmonary circulation, which has less 
resistance than the coronary arteries. The end result is that the coronary arteries do not 
receive as much blood as they typically would. For a single ventricle performing 
increased workload, the combination of decreased blood supply (which means decreased 
oxygen supply) and the potential for the hypoplastic ventricle to steal what blood does go 
to the coronary circulation, the mBTS presents unfavorable odds for ventricular health.  
Arguments have been made in favor of other Stage 1 procedures. These would 
eliminate the mBTS by shunting to the pulmonary circulation using a different method, 
thus removing the shunt steal’s effect on coronary perfusion [2, 6]. For instance, the 
Right Ventricle – Pulmonary Artery (RVPA) shunt is said to provide better 
hemodynamics, less shunt steal, and improves overall survival rate to the 2nd surgery [2], 
[26]. However, the invasiveness of anatomically altering the only healthy ventricle is of 
concern for some medical professionals. Thus, it is still useful to research improvements 
to and develop better understanding of the Stage 1 with mBTS. This research can be 
performed using multi-scale modeling methods. 
27 
 
Multi-scale Modeling of the Norwood with mBTS 
In multi-scale modeling, a 3D model is coupled to a zero-dimensional (0-D) LPN, 
which provides the model’s inlet and outlet boundary conditions [27]. In terms of HLHS, 
multi-scale modeling has been used to model the Norwood palliation for both general and 
patient specific cases to study the hemodynamics that cannot be captured in vivo [28]. 
These models incorporate a 3D model of interest  (i.e. aortic arch) of the HLHS patient 
that captures the local hemodynamics of the system. The 0-D LPN governs the model’s 
inlet and outlet boundary conditions. The LPN provides the system-level pressures and 
blood flow rates of the entire “circulatory network” through its use of resistance (R), 
inertance (L), and capacitance (compliance) (C) elements to create an impedance of each 
circulation [27]. Migliavacca et al. explained that the reasoning for integrating the LPN to 
a 3D model is that “the whole circulatory network [of the Norwood palliation] has to be 
taken into account for the evaluation of the hemodynamics in the specific region [3D 
model].” [27]  
The multi-scale models for the Norwood hemodynamics have been accomplished 
using experimental (in vitro) mock circulatory systems and computational or numerical 
(in silico) models. As described by Biglino et al., some of the key advantages of these 
models include their ability to acquire detailed information of the hemodynamics that 
cannot be captured clinically (in vivo), be a tool for educational purposes and medical 
device testing, and provide “what-if” scenarios for parametric studies of varying surgical 
options [29]. In the following studies, the aortic arch of a Norwood patient was coupled 
to a LPN composed of impedances that represent the upper body, lower body, pulmonary, 
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and coronary circulations. The first of these is an in silico study by Migliavacca et al. 
who looked into the effects of the various shunt options for the Stage 1 surgery. 
Schematics of their models are seen in Figure 1.6. 
 
Figure 1.6 In silico multi-scale models of the Norwood with RVPA (Left) and mBTS (Right) [27] 
 
In this study, Migliavacca et al. found that the choice of shunt had a large effect on 
the relationship between pulmonary flow and coronary perfusion. The RVPA shunt, 
when compared to mBTS, had the greatest CBF because it allowed for a higher diastolic 
aortic pressure [27], and thus greater CPP. However, the central shunt (CS), which 
connects from the ascending aorta to PA to provide for systemic to pulmonary flow, 
lowered the coronary perfusion pressure and flow. It also had more pulmonary flow than 
the mBTS. This shows the relationship between the systemic-pulmonary shunt’s 
placement and coronary perfusion. It appears that shunts placed in closer proximity to the 
ascending aorta result in more pulmonary flow and less CBF. 
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In an in silico study that only looked at the mBTS, focus was given to the effects 
caused by placement and size (inner diameter) of the shunt. Here, Moghadam et al. found 
that the shunt diameter had a greater effect on coronary oxygen delivery than did the 
placement (proximal or distal) along the innominate artery [9]. Specifically, a smaller 
shunt increased the aortic pressure, which allowed for more coronary flow due to a higher 
CPP. A shunt placed distal along the innominate artery also allowed for optimal coronary 
oxygen delivery, whereas a proximal placement optimized non-coronary systemic oxygen 
delivery. For a combined optimization of systemic and coronary oxygen delivery, 
Moghadam et al. found that a shunt placed between the distal and proximal location with 
a 3.41 mm diameter was most efficient [9]. These results agreed with Migliavacca et al.’s 
findings that mBTS size affects the PVR in such a way that blood in the aortic arch 
during diastole is stolen from the coronaries. 
Lagana et al. also looked at the effects of the mBTS compared to the CS with their 
computational multi-scale model. In this study, the results agreed with Moghadam et al.: 
the mBTS was better than the CS for coronary perfusion, but increasing mBTS diameter 
did increase pulmonary flow at the loss of coronary. Further, Lagana et al. found that 
coronary flow made up 2.98% to 3.83% of the cardiac output when using the mBTS, and 
that halving the coronary resistance greatly increased the coronary perfusion. This 
indicates that coronary resistance is a major contributor to determining CBF. Overall, the 
mBTS was recommended over the CS as the Stage 1 shunt option [11]. 
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In a study focused solely on the mBTS, Corsini et al. used their in silico model to see 
how coarctation (COA), a localized narrowing of the aorta, and mBTS size affected 
coronary perfusion. A large shunt with severe COA was found to be unfavorable for the 
coronary perfusion and oxygen delivery. The severe COA caused an increase in the 
afterload, and resulted in decreased cardiac output. The idea of shunt steal was supported 
as increased COA severity resulted in an increase QP/QS and decreased coronary flow. 
When maintaining constant cerebral perfusion, similar results were obtained [10].  
Overall, these in silico models come to the same conclusion: the mBTS provides 
better hemodynamics than the CS, while underperforming compared to the RVPA. When 
looking only at the mBTS, larger shunt options decreased the diastolic aortic pressure, 
and so decreased CPP and coronary oxygen delivery. COA in the presence of the mBTS 
further hinders the coronary performance. These results were performed exclusively 
using computational methods and rely on the methods chosen to solve the local fluid 
dynamics of the 3D model – a risk in using in silico models. Therefore, the in vitro 
models are useful in their ability to reliably provide the local hemodynamics of the 3D 
model being studied. Together, the in vitro models can be used to verify the results 
obtained from in silico models. Unfortunately, an in vitro model of the Norwood 
palliation that includes the coronary circulation does not exist. 
Prior to the work detailed in this thesis, Hang’s in vitro model for the Stage 1 
palliation was limited to providing details about the pulmonary, upper body, and lower 
body circulations [28]. In his research, Hang validated his MCS against patient-specific 
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parameters obtained clinically. He then investigated the effects of COA on both the 
mBTS and RVPA Norwood palliations by introducing a range of COA severities to the 
model. Five patient-specific 3D models were used in his study to further investigate the 
effects of morphology. His findings showed that the RVPA does improve the QP/QS 
when compared to the mBTS. He also showed that severe COA resulted in more drastic 
changes to QP/QS, and that atypical aortic arch morphology was associated with larger 
ventricle power [28].  
In terms of the results on pulmonary to systemic flow, Hang’s results agree with those 
found by the aforementioned in silico models. However, the in vitro model did not 
include the coronary circulation. As shown above, coronary perfusion and oxygen 
delivery are heavily dependent on modifications that affect QP/QS. This leads to the 
objectives of the present study. 
Research Objectives and Hypothesis 
The following are the objectives of this study: 
1. Design and integrate a coronary circulation into a previously validated in vitro 
multi-scale model [28]   
2. Verify the system’s response against a mathematical (analytical) model 
3. Validate the in vitro coronary blood flow against clinical findings in literature 
4. Validate the entire in vitro model against clinical data of a HLHS patient 
5. Investigate the effects of mBTS size on coronary perfusion  
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Additionally, the following is hypothesized: 
6. The in vitro model will illustrate how increased mBTS size negatively affects 
coronary perfusion  
The hypothesis will be accepted in the case where increased shunt size results in 
decreased coronary blood flow and a connection between the two can be proven. The 
hypothesis will be rejected in the case where there is no discernable drop in coronary 
blood flow with increasing shunt size.  
In completing these objectives, the in vitro model will allow experimentation of the 
Norwood hemodynamics and morphology with respect to coronary perfusion. In 
particular, assessing the mBTS’s effect will allow detection of whether or not shunt steal 
of coronary perfusion exists. No experimental findings have been recorded for this 
phenomenon and doing so would either verify or negate in silico results. In the next 
chapters, focus will be given to the methods taken to create this system, in particular to 
the coronary circulation. 
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CHAPTER TWO 
IN VITRO CORONARY CIRCULATION MODELING 
Early Coronary Blood Flow Models 
A major complication of CBF is its interaction with myocardial contraction and 
relaxation. The upper body, lower body, and pulmonary circulations in in vitro LPNs 
have static impedances whose blood flow and pressure are strictly governed by the fixed 
impedance values, the upstream aortic pressure, and downstream atrium pressure [28]. 
This is unlike the coronary circulation, whose impedance must account for myocardial 
contraction through a dynamic response. This complication was initially addressed by 
Downey and Kirk’s waterfall model [30] and then improved on by Spaan et al.’s 
intramyocardial pump (IMP) model [31] (Figure 2.1). 
a) b)  
Figure 2.1 (a) Schematic of the waterfall model by Downey and Kirk [32]: (top) collapsible 
tube with inflow pressure PA, outflow pressure PV, exterior pressure PT. (middle) flow graph 
as a function of PA for two cases of PT. (bottom) electrical analogue of where VA is PA, VT is 
PT, and current is flow. (b) Schematic of the intramyocardial pump model by Spaan et al. 
[31]: intramyocardial tissue pressure Pim and capacitance Cim, arterial and venous coronary 
resistances Ra and Rv, intramyocardial blood pressure Pib, perfusion pressure Pp, and left 
coronary artery pressure Plc. Figures reprinted with permission of original authors. 
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The waterfall model (Figure 2.1a) is a “time-varying resistance model” for CBF [31]. 
Downey and Kirk believed that intramyocardial tissue pressure increases in systole as a 
result of the cardiac contraction. As the intramyocardial tissue pressure increases during 
systole, the pressure difference between the tissue and within the coronary vessels results 
in the vessels collapsing, thus increasing the vessels’ resistance [30, 32]. And by the 
relation that flow is determined by pressure drop across resistance, the arterial pressure 
drives the coronary flow over coronary resistance towards the venous pressure. The 
variations in the flow are strictly determined by the variations in the coronary resistance, 
which is governed by intramyocardial tissue pressure.  
To simulate this idea, Downey and Kirk’s model (top of Figure 2.1a) is composed of 
an arterial pressure (Pa) and venous pressure (Pv), whose difference drives the flow 
through the coronary vessel (i.e., a tube). The outer pressure (PT) represents the 
intramyocardial tissue pressure, which increases and decreases during systole and 
diastole, respectively. When PT exceeds the pressure within the tube, the tube will 
increasingly collapse, mimicking an increased coronary vessel resistance during 
ventricular contraction of systole [32]. This method is able to capture phasic differences 
in arterial coronary flow: zero-flow during systole when PT is high and increased flow in 
diastole when PT is low. However, it does not account for the systolic flow reversal seen 
in vivo or for the venous coronary flow which is predominately during systole [31, 33]. 
This led Spaan et al. to develop their IMP model. 
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To account for accurate arterial and venous coronary flow, the IMP model built on 
the ideas of the time-dependent diode (resistance) model of Downey and Kirk. For the 
IMP model, Spaan et al. implemented a volume pumping mechanism by incorporating a 
capacitor connected to a time-dependent pressure (Figure 2.1b) [31]. They reasoned that 
in addition to varying resistances to account for autoregulation, coronary vessels also 
have their own capacitance. When combined with the time-varying intramyocardial tissue 
pressure, the capacitance of the vessels helps regulate the differences between arterial and 
venous coronary blood flow through blood volume changes [31]. The volume changes 
are then directed upstream or downstream depending on the resistance of the arterial and 
venous coronary beds. 
From the schematic in Figure 2.1b, the time-varying intramyocardial pressure (Pim) is 
translated across the intramyocardial capacitor (Cim) to the “intramyocardial blood 
compartment” pressure (Pib) [31]. This results in variations of the Pib pressure, resulting 
in a higher pressure in systole relative to diastole. With this change in pressure there is 
also a change in blood volume stored at the capacitor, Cim. The direction (flow) and 
amount of the blood volume is then determined by the arterial and venous coronary 
resistances (Ra and RV, respectively), and by the Pib pressure relative to its up and 
downstream pressures.  
In systole, arterial flow is low and may even be retrograde when Pib exceeds the 
upstream pressure. Further, in systole, the venous coronary flow is driven forward across 
the venous resistance (Rv) because of the high Pib, mimicking cardiac contraction 
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squeezing venous blood out of the coronary circulation. In diastole, Pib is lower and is not 
as influenced by Pim. This allows for flow across the arterial resistor to then be stored 
within Cim.  Therefore, as that arterial flow moves into the capacitor during diastole and 
Pib is low, the venous flow is at its minimum. An illustration of this model’s arterial 
coronary flow relative to the systemic LV pressure can be seen in Figure 2.2.   
 
Figure 2.2 Results from the IMP model and reprinted with permission by Spaan et al. Top is left 
ventricle pressure, middle is coronary artery pressure, and bottom is coronary artery flow. [31] 
 
The waterfall and IMP models were both groundbreaking in their ability to create 
physiological portrayals of coronary blood flow and pressure. Since these models were 
proposed, both in silico and in vitro models have been attempted based on their ideas. 
The following in vitro models are not specifically Norwood models, but were 
investigated to ensure that the most accurate method was chosen for the Stage 1 MCS.  
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In Vitro Coronary Blood Flow Models 
In recent years, limited accounts of experimental modeling of coronary blood flow 
have been attempted [34–37]. Their aims were to create a representative circulation that 
could model varying physiological conditions. An early attempt was by Geven et al. who 
created a model for an adult human under normal and hyperemic conditions. Their goal 
was to help validate the then newly developed “clinical diagnostic techniques” that were 
used to capture coronary flows and pressures [34]. The model can be seen in Figure 2.3. 
a)  
b)  
Figure 2.3 Schematics of the (a) LPN coronary model and (b) in vitro setup by Geven et al. [34] 
 
In this model, Geven et al. modeled three components of the cardiovascular system: 
the systemic LV and aorta, the systemic circulation, and the coronary circulation. The LV 
is a piston-cylinder mechanism composed of an incoming venous flow and outgoing 
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arterial flow to provide the inlet condition to the aorta: the aortic pressure and flow 
waveforms [34]. The determinant of these waveforms is the systemic circulation, which 
is made of a single compliance and a proximal and distal resistance. As fluid moves 
through the aorta, it is allowed to pass into the coronary circulation.  
Referencing Figure 2.3a, the “coronary artery” component of this circulation is 
modeled with “physiological dimensions and capacitance” using a polyurethane tube. 
The arterial resistance, Rar, and all subsequent resistances (except Rma) are made using 
“manually adjustable clamps”. Similar to the waterfall model by Downey and Kirk, a 
change in myocardial resistance due to myocardial contraction is accounted for by the 
qmyo and Rma components of Figure 2.3a. In Figure 2.3b, a collapsible tube is shown to 
pass through the LV chamber so that the inner LV pressure can physically manipulate the 
resistance of the collapsible tube at this point in the circulation [34]. The authors refer to 
their work as mimicking Downey and Kirk, however the collapsible tube provides it’s 
own compliance, which is similar to Spaan et al.’s IMP model. This is shown in Geven et 
al.’s results (Figure 2.4 below) where retrograde systolic CBF is achieved. 
 
Figure 2.4 Clinical (top) and in vitro (bottom) coronary artery flow for normal (left) and 
hyperemic (right) conditions [34] 
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The results of Geven et al.’s experiment for normal and hyperemic conditions show 
distinct differences in systolic versus diastolic flow, while even accounting for retrograde 
flow during systole. Further, the results qualitatively agree with the in vivo reference. 
However, this model is limited in that it lumps the entire systemic circulation into one 
impedance element, which does not allow for the individual effects on specific systemic 
branches to be described. Additionally, while the coronary circulation appears accurate, 
passing a tube through the LV chamber would present a problem with Hang’s in vitro 
setup [28]. Hang used a ventricular assist device (VAD) to provide the aortic pressure 
and flow waveforms, and this device’s structure would not allow for a coronary tube to 
be passed through it. Therefore, Geven et al.’s exact method would not work for 
implementation into Hang’s MCS. 
Pantalos et al. developed a 0-D MCS for pediatric cardiovascular systems [35]. Their 
bench-top model allowed for various setups to help test different medical instruments 
such as an intraaortic balloon pump or VADs. Their system, seen in Figure 2.4, 
comprises both the systemic and pulmonary circulations. The coronary circulation is one 
single tube running through a “dynamic resistor” [35]. Unlike Geven et al. and Spaan et 
al., it does not account for compliance of the coronaries. The coronary flow is strictly 
controlled by the variation in the resistor. Additionally, this model does not account for 
venous coronary flow, although whether or not this was important to their setup is 
unknown.   
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Figure 2.4 Schematic of the experimental pediatric cardiovascular model with the (1) dynamic 
coronary flow resistor by Pantalos et al. [35] 
 
Looking at the results of Pantalos et al.’s study, clinical validation of their system was 
only given to ventricle pressure and aortic flow and pressure [35]. The coronary flow was 
not validated against any in vivo measurements. Initially, the model was used in a normal 
setup, like the one seen in Figure 2.4. Then they modified the system to model the 
cardiovascular system’s response to different medical devices. The literature does not 
reveal whether the dynamic resistor was able to accurately capture a physiological flow 
in the coronary circulation, especially when the results reveal such variability between 
setups (Figure 2.5). Thus, this approach for coronary modeling was discarded.  
 
Figure 2.5 Coronary artery flow for (Left) normal, (Middle) LV failure, and (Right) intraaortic 
balloon pump models [35] 
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 In the same year, Gaillard et al. reported their work on modeling the effects of 
aortic valve stenosis on the coronary circulation [36]. The model (Figure 2.6) is very 
similar to that presented by Geven et al [34]. The system is composed of three branches: 
the ventricle, systemic “aortic flow model”, and the coronary circulation. The coronary 
circulation differs from Geven et al.’s in that it does not pass a collapsible tube through 
the ventricle’s chamber. Instead, a tube is connected from that chamber and is passed to 
another chamber. The resistor RLV is used to adjust the LV chamber pressure felt in the 
“Sim” chamber [36]. This chamber has a collapsible tube passing through it so that 
during systole, the variations in pressure have an effect on the resistance of the flow 
passing through that area. Further, compliance of the collapsible tube allows for volume 
changing features to be applied, like those proposed by Spaan et al.’s IMP model [31].  
 
Figure 2.6 Schematic of in vitro setup by Gaillard et al. [36] 
Unlike Pantalos et al., Gaillard et al. gave attention to the in vivo validation of his 
experiment’s results. They used clinical echo measurements from the left anterior 
descending coronary artery under various levels of aortic valve stenosis to compare 
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against their results [36]. They found that their waveform of arterial coronary flow was 
both accurate in shape and magnitude. This clinical validation method is important in 
determining whether the model is accurate, especially if the parameters of the system are 
going to be extrapolated beyond the comparable results. And while the model appears to 
present a reliable results, the method of how they adjusted the RLV is unclear. However, 
while passing a connecting tube to a VAD is unfeasible for the Hang MCS, the idea of 
bringing the ventricular pressure to the coronary model was noteworthy.  
A final in vitro model studied was by Calderan et al. [37]. The purpose of their work 
was to develop a systemic model that could simulate the effects of “transcatheter aortic 
valve implantation (TAVI)” [37] on coronary flow. Their entire system was composed of 
a LV and aorta branch, a systemic impedance to help control the aortic waveforms, and 
the coronary circulation. The coronary branch was modeled as the simplified LPN seen in 
Figure 2.7a. It is composed of a proximal static resistance, compliance, and a distal time-
varying resistor (Rma) [37].  
 
Figure 2.7 Calderan et al.’s (a) coronary LPN, (b) Rma(t) resistance graph for one cardiac cycle, 
and (c) experimental results of coronary flow and aortic pressure, and in vivo coronary flow [37] 
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The time-varying resistor in Figure 2.7 was achieved using a “stepper motor” 
connected to an “adjustable stopcock valve” [37]. The amount the valve was closed, the 
amount of resistance to coronary flow, depended on the signal of Rma, which had a higher 
value during systole than in diastole (Figure 2.7b) to mimic cardiac contraction impeding 
the flow. The signal was sent to the stepper motor by a LabView system. Higher 
magnitudes of resistance correlated with the stepper motor closing the valve more [37].  
The coronary flow based on this time-varying resistance model can be seen in Figure 
2.7c. As shown, it is in comparable qualitative agreement with the provided clinical 
reference, however slight amplitude differences are apparent. Further, this model was 
said to measure the coronary flow distal to Rma [37]. This means that attention was not 
given to the proximal flow conditions, which may or may not have been physiological. 
Since the study was to see the effect the TAVI had on coronary flow, the unknown area 
between the TAVI and measured coronary flow could have had non-physiological 
features that could interfere with the results. Additionally, this model did not account for 
a relation of intramyocardial tissue pressure and coronary vessel compliance in the way 
that Spaan et al. proposed to make distinctions between arterial and venous flow [31]. 
However, the control of the resistance using LabView is noteworthy considering the 
same program is used in Hang’s setup [28].  
Overall these models provide helpful insight into the methods used to capture 
physiological coronary flow waveforms. Considering these experimental techniques, 
44 
 
attention was then given to the LPN that would be used as the blueprint for the in vitro 
system.   
Selecting the Coronary Circulation LPN 
When determining the framework of the LPN, it was important to consider the 
implications of the experimental model used in relation to other Norwood in silico 
models. A model based on a LPN that is very different from those in silico versions 
might not provide the ability for comparable coronary results, in case one system’s 
response was different from another. Therefore, the LPNs from multiple in silico models 
[9–11, 27, 38, 39] of the Stage 1 with mBTS palliation were analyzed with regards to 
their waveform results, size, and ease of implementation .  
The in-depth review of the in silico models revealed a familial relationship between 
the LPNs of the coronary circulations with slight variation through the other branches. 
Dating from 2005 to 2014, the same coronary LPN was used between the works of 
Lagana et al., Migliavacca et al., Bove et al., Hsia et al, Moghadam et al., and Corsini et 
al. [9–11, 27, 38, 39]. Lagana et al. was the first to depict the coronary model in a 
Norwood model [11]. They built their coronary LPN based on the descriptions by 
Mantero et al. [13], whose adult-human mathematical model followed the ideas of Spaan 
et al.’s IMP model [31]. A schematic of the coronary LPN used by these Norwood in 
silico works is shown in Figure 2.8. 
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Figure 2.8 Schematic of the LPN used in multiple in silico Norwood models 
 
The “SVP” in Figure 2.8 refers to the single ventricle pressure (SVP). For the 
Norwood palliation, this would refer to the systemic RV pressure, which is connected at 
the SVP point from the heart model of their LPN. The compliance CCB connected to the 
SVP mimics the idea of myocardial contraction, which, according to Mantero et al., is felt 
more in the distal endocardial vessels than the proximal epicardial vessels [13]. Thus, the 
SVP mostly affects the pressure at the CB resistance and compliance junction, and its 
impact is decreased from the CA2 impedance to the CA1 impedance.  
The different impedance elements in Figure 2.8 allow for the distinction between the 
arterial coronaries (CA1 and CA2) and the venous (CB and CV). Hence, like the IMP 
model, both arterial and venous blood flow should be distinguishable based on the point 
that is measured. To provide the boundary condition to the 3D model in the MCS, it is 
only necessary to create an arterial coronary blood flow and pressure. However, having 
the ability to distinguish differences in arterial and venous flow may aid in validating the 
waveforms.  
To the author’s knowledge, all coronary LPN models for the Norwood palliation are 
of the same structure. And so, it was determined that the LPN in Figure 2.8 would be the 
reference for the in vitro model. A slight variation from this model was caused by the 
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values of the resistors and compliances used in the in silico models (Table 2.1). Note that 
the values for each element in the LPN are scaled based on body surface area (BSA) [40]. 
Each model uses the same elemental values because BSA remained at 0.33 m2.  
Table 2.1 The LPN values used by the in silico models [9]–[11], [27], [38], [39] 
 CA1 CA2 CB CV 
Resistance (R)  
[mmHg.s/mL] 10.6739 10.6739 21.3477 10.6739 
Compliance (C) 
[mL/mmHg] 1.94351 x 10
-3 5.18269 x 10-3 7.77404 x 10-3 0.5 x 10-4 
 
Referring to Table 2.1, relative to the R and C values used for the other systemic and 
pulmonary circulations, the compliance values are magnitudes smaller and the resistances 
are very large. In particular, the CV compliance is a magnitude smaller than the three 
proximal to it. For experimental modeling feasibility, CCV was discarded and the 
resistance, RCV, which was not negligible, was lumped into RCB.  The final LPN and 
values used for the in vitro model are seen in Figure 2.9 and Table 2.2.  
  
Figure 2.9 The coronary LPN used for the in vitro model 
 
Table 2.2 The LPN values for the LPN seen in Figure 2.9 
 CA1 CA2 CB 
Resistance (R) 
 [mmHg.s/mL] 10.6739 10.6739 32.0216 
Compliance (C) 
[mL/mmHg] 1.94351 x 10
-4 5.18269 x 10-4 7.77404 x 10-3 
 
47 
 
The following section details the experimental implementation and reasoning for 
discarding CCV. Along with CCV being eliminated, the compliances CCA1 and CCA2 were 
reduced in size. A purely mathematical model, created for verification purposes, did not 
couple a 3D model to the LPN. And so, there were slight differences in how the coronary 
system responded. Reducing these compliance values achieved a physiological flow 
waveform, details of which are discussed in the next chapter.  
Creating the In Vitro Coronary Circulation 
The methods chosen for creating the physical realization of the LPN were based on 
those used by Vukicevic et al. [41] and Hang [28]. Tubing was used to connect the inflow 
and outflow ports of the 3D model to the in vitro LPN. The amount of tubing was 
minimized to reduce any effects of inertance and unintentional resistance. To set the 
resistance, pinch needle valves were used, which cause a change in flow for a give 
pressure drop based on Equation 2.1 
𝑅 = ∆𝑃/𝑄        (2.1) 
Here, Q is the flow rate through the valve and ∆𝑃 is the fluid pressure drop across the 
valve. Additionally, the compliance of an impedance element is based on Equation 2.2. 
𝐶 = ∆𝑉/∆𝑃        (2.2) 
For this fluid system, the effects of C can be described by the change of volume (∆𝑉) 
of fluid in the compliant element for a change in fluid pressure (∆𝑃) [41]. This is created 
using air chambers that trap a pocket of air [41] coupled to the fluid system which applies 
48 
 
the pressure that compresses the air. For setup purposes, the volume of air is calculated as 
V=C*Pabs, where Pabs is the mean absolute pressure of the air at that compliance element. 
The first two compliances (CCA1 and CCA2) were made using 10 mL syringes. Based 
on Equation 2.2, the volume of air calculated for the CCV value was less than what could 
be reliably measured. It was assumed that the compliance of the tubing was enough to 
implement this feature. On the other hand, the compliance at CCB presented its own 
complication since it is coupled to the SVP 
The aim of the in vitro coronary model was to mimic the LPN as closely as possible. 
Methods such as Geven et al.’s [34], where the coronary tubing was passed through the 
LV chamber, were used as reference in designing the final model but not exactly 
replicated. Geven et al.’s methods presented a three-dimensional effect of SVP on the in 
vitro coronary LPN. Since this part of the system is supposed to be 0-D, the coronary 
tubing needed to be affected by SVP at a specific point. This was achieved with the CCB-
SVP coupling chamber (CC) apparatus (Figure 2.10). 
 
Figure 2.10 Schematic of the experimental CCB-SVP coupling chamber (Left) and LPN (Right) 
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In Figure 2.10, a pneumatic SVP signal is applied to the air-filled side of the CC. This 
signal is then translated across a diaphragm to the fluid chamber of the CC. This chamber 
is connected to the main coronary tubing at the CB pressure point (PCB). By minimizing 
the SVP contact to a point within the main coronary tubing, control of PCB for tuning 
purposes is maintained. Throughout the cardiac cycle, as the SVP is applied, the 
diaphragm will appropriately flex to affect PCB accordingly. The flex of the diaphragm 
accounts for volume displacement, allowing for the variation in arterial and venous flow 
as described by Spaan et al. The final in vitro coronary circulation is seen in Figure 2.11.  
 
Figure 2.11 The in vitro coronary circulation 
 
The CC was made of PVC pipe and fittings. The diaphragm’s material, a silicone 
rubber, was chosen with respect to how it interacted with the fluid chamber. Thus, the 
diaphragm’s compliance was CCB. Furthermore, a 3-way valve (Model: 225B-111CAAA, 
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MAC Valve, Dundee, MI, USA) was used to connect an incoming compressed air line 
and vacuum line with the output going to the SVP. Pressure regulators were used to 
control the magnitude of the incoming pressure and vacuum pressure. The ratio of time 
for compressed air to vacuum was sent to the 3-way valve as a computer generated signal 
from the data acquisition/control system (DAQ) and LabVIEW (USB 6211, LabVIEW 
8.6; National Instruments, Austin, TX). A schematic of this setup is shown in Figure 
2.12. 
 
Figure 2.12 Schematic of the setup used to create the pneumatic SVP signal 
 
Coronary flow (QCOR) measurements, using a 5.1mm diameter electromagnetic flow 
probe (Model: EP616-STD-PV8-501, Carolina Medical Electronics, King, NC), were 
taken between the 3D model and the first impedance to ensure the proper arterial 
boundary condition was met. Pressure measurements were taken at the syringe-tubing 
unions (PCA1 and PCA2) and at the CC-tubing union (PCB). Wall taps were connected to 
pressure transducers (DTXplus, BD Medical Systems, Sandy, UT). All signals were 
acquired using the DAQ at 160 Hz. Full details of system equipment, setup, and tuning 
can be found in Appendix A.  
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CHAPTER THREE 
THE IN VITRO MOCK CIRCULATORY SYSTEM 
The In Vitro Model 
A LPN of the entire cardiovascular system, with the addition of the coronary 
circulation, was created based on the structure of Hang’s LPN [28]. The MCS features 
the LPN coupled to a 3D model (test section) of the reconstructed aortic arch. A 
schematic of the MCS is shown in Figure 3.1 (Left) and a photograph of the MCS is 
shown in Figure 3.2 (Right). A VAD is used as a hydraulic pump whose output passes 
through a proximal compliance (Cprox) to provide the input aortic flow (QAO) and pressure 
(PAO) to the test section. From the test section, the fluid passes into the systemic 
branches: upper body (UB), lower body (LB), and coronary (COR), and a 
pulmonary/mBTS (mBTS) branch. All circulations return the fluid into the atrium (Atr) 
that then reconnects to the VAD.  
To run experiments with this system, the first step was to tune the in vitro LPN’s 
resistance and compliance. These impedance values were determined by either an 
analytical model or clinical data. Once tune, the VAD and proximal compliance (CPROX) 
were adjusted to create the appropriate input aortic pressure waveform. With the 
impedance downstream of the test section set, once the correct waveform was created, 
then the resulting flows and pressures were measured.  
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Figure 3.1 The MCS schematic (Left) and in vitro MCS (Right): (A) VAD, (B) Proximal Aortic 
Compliance, (C) Test Section, (D) Upper Body, (E) CC and Coronary, (F) Lower Body, (G) Atrium, 
(H) mBTS and Pulmonary. Points of flow (Q) and pressure (P) measurements. 
Similar to the coronary in vitro model, air chambers and pinch needle valves were 
used as compliance and resistance in the other systemic and pulmonary branches. The 
atrium was assumed to have infinite compliance and was left as an open reservoir. All 
flow measurements (referenced markers in Figure 3.1) were taken using electromagnetic 
flow probes (EP600 series, Carolina Medical Electronics, King, NC) controlled by an 
analog flow meter (FM501, Carolina Medical Electronics, King, NC). Pressure 
measurements were taken at pressure wall taps (referenced markers in Figure 3.1). The 
signal was acquired using pressure transducers (DTXplus, BD Medical Systems, Sandy, 
UT) and passed through a bridge amplifier (Model 2100, Measurements Group Inc., 
Raleigh, NC). Both flow and pressure signals were measured and recorded using a data 
acquisition system (DAQ) and LabVIEW (USB6211, LabVIEW 8.6; National 
Instruments, Austin, TX). Compressed air and vacuum were used to control the VAD, 
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similar to the system that created the coronary system’s SVP. Both systems used the 
same air and vacuum lines but were independently controlled for systolic time ratio.  
The Methods to Verify 
In order to verify that the in vitro MCS was setup correctly, a purely mathematical 
model of the LPN (Appendix B) of Figure 3.1 was created. This analytical model was set 
up for a baseline case using parameter values from Corsini et al.’s LPN [10], whose 
values were derived from pre-Glenn patients’ catheterization data. Then, with a 
prescribed aortic flow and pressure input, the analytical model’s LPN provided the flow 
and pressure measurements for the subsequent circulations. These were used for setting 
the resistance and compliance of the MCS, controlling the VAD to achieve the desired 
aortic waveforms, and controlling the air pressure of the SVP. A saline solution (30 cc 
salt per gallon of water) was used as the system’s fluid. The heart rate (HR) was 120 
beats per minute (bpm), which correlated to a 0.5 second cardiac cycle. 
A generalized HLHS post-Norwood 3D model used by Corsini et al. [10] was 
provided. The model (Figure 3.2) has a 3.5 mm inner diameter mBTS connected at the 
innominate artery, and a representative coronary artery (2 mm inner diameter) at the site 
of the DKS anastomosis. The test section was printed in 3D and used for the verification 
study only. The 3D model was based on a BSA of 0.33 m2. Based on the scaling laws 
defined by Pennati and Fumero [40], the coronary LPN values from Table 2.2 did not 
change. A full set of LPN values and system tuning details are found in Appendices A 
and B. 
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Figure 3.2 The 3D-printed test section for the verification study: (A) Left to Right: Left 
Subclavian (LSA), Left Carotid (LCA), Innominate (Inom), (B) Ascending Aorta (AO), (C) 
Descending Aorta to Lower Body (LB), (D) mBTS, (E) Coronary (COR) 
Verification Results 
The system was set for the flow and pressures from the analytical model (Appendix 
B). The experimental (or MCS) mean pressure (P) [mmHg], mean flow (Q) [Lpm], and 
resistance (R) [WU = mmHg/Lpm] results can be seen alongside the analytical values in 
Table 3.1. All MCS results were averaged over 10 cardiac cycles worth of data to ensure 
stable results. A t-test at 95% confidence was performed to compare mean MCS and 
analytical results. Methods for statistical analysis and uncertainty are found in Appendix 
C. The resistance values were calculated using Equations 3.1-3.5. MCS and analytical 
waveform relationship was quantified through the coefficient of determination (R2) and a 
range-normalized Root-Mean-Square Error (σ) (Equation 3.6). Full results are in 
Appendix D. 
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Table 3.1 Mean flow, mean pressure, and resistance results for the verification study. MCS values = 
mean ± uncertainty  
Flow [Lpm] Analytical MCS 
Cardiac Output (QAO) 1.82 1.82 ± 0.01 
Upper Body  (QUB) 0.38 0.38 ± 0.01 
Lower Body (QLB) 0.40 0.40 ± 0.01 
Pulmonary (QmBTS) 0.98 0.98 ± 0.01 
Coronary (QCOR) 0.056 0.056 ± 0.002 
Pressure [mm Hg] Analytical MCS 
Ascending Aorta  (PAO) 60.11 60.37 ± 0.30 
Pulmonary (PPul) 11.06 11.05 ± 0.06 
Lower Body (PLB) 56.71 57.56 ± 0.29 
Coronary CA1 (PCA1) 53.61 57.51 ± 0.28 
Coronary CA2 (PCA2) 43.71 43.89 ± 0.22 
Coronary CB (PCB) 33.80 33.61 ± 0.18 
Resistance [WU] Analytical MCS 
Upper Body (UBSVR) 148 150 ± 4 
Lower Body (LBSVR) 139 140 ± 3 
mBTS (RmBTS ) 50 50 ± 1 
Pulmonary (Rpul) 7 7 ± 0.1 
Total Coronary (RTC) 1000 1005 ± 35 
 𝑈𝐵𝑆𝑉𝑅 = (𝑃!" − 𝑃!"#)/𝑄!"        (3.1) 
𝐿𝐵𝑆𝑉𝑅 = (𝑃!" − 𝑃!"#)/𝑄!"        (3.2) 
𝑅!"#$  = (𝑃!" − 𝑃!"#)/𝑄!"#$        (3.3) 
𝑅!"#  = (𝑃!"# − 𝑃!"#)/𝑄!"#$        (3.4) 
𝑅!"  = (𝑃!" − 𝑃!"#)/𝑄!"#        (3.5) 
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𝜎 = !! !!!!!" !!!!!!!"#!!!"# ∗ 100%        (3.6) 
Table 3.1 shows the experimental (MCS) mean results are in good agreement with the 
analytical model. A 30 mm circumference flow probe was used to measure QAO, QUB, 
QLB and QmBTS. A 15 mm circumference flow probe was used to measure QCOR. The 
probe sizing and relative magnitude of flow velocities resulted in less uncertainty for the 
coronary flow, details of which are discussed in Appendix C. The t-test results do not 
show any significant difference (p > 0.05) for the flow measurements.  
For pressure, only the pulmonary pressure was found to have no statistical difference 
(p=0.25) between the mean analytical and MCS values. However, PAO, Ppul, PCA2, and PCB 
were encompassed in the uncertainty of MCS results and so the values were deemed 
acceptable. The largest difference was found at PCA1, with a relative error of less than 8%. 
This difference may be the result of comparing a purely analytical model whose 
impedance was not able to capture that of the multi-scale model’s 3D test section. 
Therefore, the results obtained were deemed sufficient. This can be shown further when 
comparing PAO’s analytical and MCS waveforms (Figure 3.3). 
 
Figure 3.3 Analytical and in vitro waveforms of aortic pressure (Pao) (R2=0.91, σ=8.6%)  
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The aortic pressures for the analytical and MCS waveforms are highly correlated 
(R2=0.91, σ=8.6%). The proximal compliance was calculated to be 0.094 mL/mmHg 
compared to the analytical value of 0.095 mL/mmHg, and the pulse pressures were 
within 1% of each other. The PAO is the input boundary condition to the test section and 
governs the response of the subsequent circulations. As Table 3.1 indicates close 
agreement with the analytical and MCS values for those subsequent circulations, it can be 
concluded that the MCS’s impedance was appropriately set. Even more so, the addition 
of the coronary branch did not seem to negatively affect the performance of the other 
circulations. Those parts of Hang’s MCS [28] were replicated. It was then important to 
verify that the in vitro CBF model was acting correctly alongside the rest of the system. 
Verification of the Coronary Blood Flow Waveform 
The aim in verification is to produce the analytical results using the MCS. However, 
it is important that these results are consistent with what might be found clinically. While 
echos of healthy coronary blood flow have been shown, it is important to consider that 
HLHS patients may present abnormal flow. However, HLHS and congenital heart disease 
patients’ coronary flow reveal the same general characteristics previously described. This 
can be seen in the following image of the flow velocities in an epicardial coronary artery 
of a neonate with HLHS and coronary fistulas: pathways from coronary vasculature into 
the ventricle [33].  
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Figure 3.4 Doppler echos of epicardial coronary arteries in HLHS neonate [33]. 
In Figure 3.4, the “S” and “D” stand for systole and diastole, respectively. It can be 
seen that the flow is primarily forward (antegrade) toward the heart in diastole. While 
systole, particularly in this case, the flow is primarily retrograde. Roberson et al. explains 
that this particularly high systolic retrograde flow may be the result of the fistulas, which 
aren’t always present in HLHS patients [33]. This reveals that CBF characteristics are 
unique to the patient and measurement site. This is seen when comparing Figure 3.4 to 
Figure 3.5. 
 
Figure 3.5 Right coronary artery flow velocities for congenital heart disease patients [42]. 
In Figure 3.5, the right coronary artery flow velocities are both different when 
compared against each other, and even more so when compared to Figure 3.4. 
Nonetheless, the same pattern persists. The common characteristics for HLHS patient 
arterial CBF include low systolic flow, early retrograde systolic flow, dominant diastolic 
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flow, and peak flow at the beginning of diastole [16, 21, 33]. The goal of the in vitro CBF 
waveform created is to provide a representative arterial coronary boundary condition to 
the test section. With this in mind, the analytical and in vitro waveforms (Figure 3.6) are 
both in agreement with the coronary flow characteristics, as well as with each other.  
 
Figure 3.6 Analytical and in vitro coronary flow for the verification study (R2=0.83, σ=14.7%) 
The CBF waveforms in Figure 3.6 both show retrograde flow during systole, peak 
flow at the start of diastole, and a downward-trending flow through the rest of the cardiac 
cycle. Furthermore, the MCS QCOR clearly indicates a majority of the arterial CBF occurs 
in diastole. Therefore the shape of QCOR in relation to the cardiac cycle is acceptable as it 
agrees with literature references for CBF. Additionally, no significant difference (p=0.85) 
was found between the analytical and MCS mean values, and a correlation between the 
data was strong (R2=0.84, σ=14.7%). This indicates an agreement between the analytical 
coronary model and the in vitro coronary model.  
From Figure 3.6, deviations in the magnitude of the retrograde systolic flow and slope 
of the descending diastolic flow do exist between the analytical and MCS QCOR. The 
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variation may be explained by the difference in pressure at PCA1 (Table 3.1), which may 
indicate a difference in coronary impedance. To further understand the effect of 
impedance on the CBF waveform and ensure that the CCB-SVP coupling (CC) would 
respond appropriately to local changes, the following study was performed. 
 In Vitro Coronary System Verification 
The aim of this study was to verify that the in vitro coronary system is an accurate 
model of the LPN from Figure 2.9. The previous section ensured the system provided 
physiological results that matched a specific analytical case. It was then important to see 
if the model’s coronary hemodynamics would also respond to changes in the coronary 
system with both accurate and physiological results. This was accomplished by assessing 
three aspects of the system: the ability to produce arterial (QCOR) and venous (QCV) 
coronary flow, the response to changes in CCB, and the response to changes in coronary 
artery resistance (RCOR). 
The system was again verified against the analytical model. The mean aortic pressure 
was found to have no significant difference (p=0.16) at 95% confidence and the 
waveform was well matched (R2=0.94, σ=10.2%). QCV was measured between the RCB 
and the atrium tank (Figure 2.9) using a 30 mm circumference flow probe, which resulted 
in larger uncertainty than QCOR, which used the 15 mm circumference flow probe. 
Overall, the results (Table 3.2) reveal acceptable agreement. 
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Table 3.2 Mean results for coronary system verification study. MCS values = mean ± uncertainty  
Flow [Lpm] Analytical MCS 
Cardiac Output (QAO) 1.82 1.81 ± 0.01 
Upper Body  (QUB) 0.37 0.37 ± 0.01 
Lower Body (QLB) 0.40 0.40 ± 0.01 
Pulmonary (QmBTS) 0.98 0.98 ± 0.01 
Coronary Arterial (QCOR) 0.056 0.057 ± 0.002 
Coronary Venous (QCV) 0.056 0.056 ± 0.005 
Pressure [mm Hg] Analytical MCS 
Ascending Aorta  (PAO) 60.11 60.65 ± 0.43 
Coronary CA1 (PCA1) 53.63 54.15 ± 0.79 
Coronary CA2 (PCA2) 43.72 43.94 ± 0.39 
Coronary CB (PCB) 33.82 33.53 ± 0.55 
 
The test section used in the MCS only requires an arterial CBF boundary condition. 
However, it is important to check that the coronary model can produce a venous CBF 
because the coronary LPN (Figure 2.9) was taken from the in silico Norwood model 
initially created by Lagana et al. [11]. Lagana et al. described creating the coronary LPN 
based on an adult mathematical model by Mantero et al. [13], who used the IMP 
methodology of Spaan et al. Thus, the in vitro coronary model was derived from the 
methodology of the IMP model proposed by Spaan et al. [31], whose main purpose was 
to accurately portray arterial and venous CBF.  Testing reveals (Figure 3.7) that both 
arterial and venous CBF can be measured in the in vitro model.  
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a)  
b)  
Figure 3.7 Analytical and MCS (a) arterial QCOR (R2=0.86, σ=12.6%) and (b) venous QCV 
(R2=0.85, σ=15.8%). 
 
The waveforms for arterial QCOR (R2=0.86, σ=12.6%) and venous QCV (R2=0.85, 
σ=15.8%) are in agreement with the analytical model. Furthermore, Spaan et al. 
described venous CBF mainly occurring in systole and minimally in diastole [31]. They 
explain that the coronary vessel’s compliance attributes to a blood volume displacement: 
a diastolic filling of arterial CBF into the coronary bed, and a systolic emptying of that 
blood through the venous vessels [31]. This agrees with the analytical and MCS 
waveforms seen in Figure 3.7b: QCOR and QCV are at their maximums in diastole and 
systole, respectively. Thus, the in vitro model is able to produce physiological venous and 
arterial CBF.  
63 
 
Once it was established that both arterial and venous CBF could be measured in vitro, 
the versatility of the CC was assessed. This was accomplished by changing the 
compliance (CCB) of the CC by using different diaphragm materials. The diaphragm 
material’s compliance (CCB) cannot be directly measured, unlike air chambers whose air 
volume corresponds to a specific compliance. However, physical interaction with the 
material can reveal whether or not it is more or less flexible, which would mean more or 
less compliance. Thus, the material is iteratively chosen to achieve the desired analytical 
CBF waveform, which then correlates to an appropriately matched CCB.  
For testing, three diaphragm materials were used: a 0.003-inch thick latex, a 0.040-
inch thick latex, and a 0.250-inch thick vulcanized silicone rubber. The flow measured 
using the 0.040-inch latex material from the verification study is labeled as QCOR and QCV 
and corresponds to the CCB value of 7.8E-3 mL/mmHg (Table 2.2). The more compliant 
and thinner 0.0025-inch latex CBF is labeled as QCOR+C and QCV+C, and the less compliant 
0.25-inch silicone rubber CBF is labeled as QCOR-C and QCV-C. For comparison to the 
analytical model, a CCB value of 7.8E-2 mL/mmHg and a CCB value of 7.8E-4 mL/mmHg 
were shown to display the CBF waveform’s response for more or less compliance, 
respectively. The MCS results for more and less compliance are not being directly 
compared to the analytical here. Instead, the comparison is the trend in which the flow 
waveforms respond to the changes in compliance CCB. Through all testing, aortic pressure 
and SVP were held constant. The results for arterial CBF are seen in Figure 3.8.  
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a)  b)  
Figure 3.8 Results of varying CCB for the (a) analytical and (b) in vitro arterial CBF (Qcor). 
 
Both the analytical and MCS results (Figure 3.8a and 3.8b) display the same response 
to changes in CCB. Increasing the compliance (from QCOR – C up to QCOR + C) results in 
decreased systolic flow and increased diastolic flow. Physiologically speaking, if the 
coronary vessels are more compliant (less stiff), then the intramyocardial pressure (or 
SVP) would more easily compress the vessels, obstructing the flow during systole. 
However, this more compliant vessel is then able to fill more during diastole. This is seen 
with QCOR+C, which shows the most systolic retrograde flow and highest diastolic flow. 
Then when compliance is decreased, as in with QCOR-C, there is less disrupted flow. For a 
less compliant myocardium, the SVP would have less effect on the flow since the rigid 
coronary vessels would not be as easily deformed under the intramyocardial pressure.  
For venous CBF, Figure 3.9 shows that more flow occurs in systole for a more 
compliant coronary system (QCV+C). This agrees with results shown in Figure 3.8 where 
the most compliant CBF had the greatest diastolic flow. Hence, as Spaan et al. explained, 
more venous CBF is ejected from the coronary bed in systole when diastolic arterial CBF 
65 
 
is increased [31]. Additionally, the less compliant QCV-C interacts similarly to QCOR-C 
where SVP appears to have minimal effect. 
a) b)  
Figure 3.9 Results of varying CCB for the (a) analytical and (b) in vitro venous CBF (Qcv). 
Next, the effect of resistance on the coronary circulation was evaluated. A flow 
resistor (pinch-needle valve) was placed between the test section’s coronary artery and 
the CA1 impedance. This coronary artery resistance (RCOR) was increased from the 
reference setup while maintaining aortic pressure and SVP. The experimental and 
analytical results of resistance and flow are shown in Table 3.3. The flows from the 
reference setup are QCOR and QCV, while QCOR+Rcor and QCOR++Rcor indicate increased 
resistance. Coronary artery resistance was calculated using Equation 3.7. 
𝑅!"#  = (𝑃!" − 𝑃!"!)/𝑄!"#        (3.7) 
Table 3.3 Resistance and flow for the MCS and analytical models (Results = mean ± uncertainty) 
 
Analytical RCOR 
[WU] 
MCS 
RCOR [WU] 
Analytical Flow 
[Lpm] 
MCS 
Flow [Lpm] 
QCOR 117 112 ± 2 0.056 0.057 ± 0.002 
QCOR + Rcor 232 232 ± 2 0.050 0.049 ± 0.002 
QCOR ++ Rcor 691 691 ± 5 0.036 0.035 ± 0.002 
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The results of Table 3.3 had no statistical difference in their values (p>0.05). This is 
shown further in Figure 3.10 where the analytical and in vitro waveforms were highly 
correlated: QCOR+R (R2=0.87, σ=14.7%), QCV+R (R2=0.87, σ=18.3%), QCOR++R (R2=0.89, 
σ=12.1%), and QCV++R (R2=0.90, σ=14.1%). This indicates that the in vitro model has an 
accurate response to changes in coronary artery resistance using the flow resistor, 
whereas the resistance could have also been implemented by changing the structure of the 
test section’s coronary artery.  
 
Figure 3.10 Arterial CBF for increasing RCOR for the (a) analytical and (b) in vitro models. 
Venous CBF for increasing RCOR for the (c) analytical and (d) in vitro models. 
 
For arterial flow (Figures 3.10a-b), increased resistance decreased the systolic 
retrograde flow and decreased the total diastolic flow. For venous flow (Figures 3.10c-d), 
the increased resistance had a subtle effect of decreasing the total flow throughout the 
cardiac cycle. The overall effect was that total CBF decreased with increased RCOR, as 
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shown by Table 3.3. This is to be expected as the act of increasing RCOR has been used to 
model the effects of coronary artery stenosis. Mantero et al. modeled this in their study 
where increased RCOR resulted in increased systolic and decreased diastolic arterial CBF, 
with a total decreased CBF [13] (Figure 3.11).  
  
Figure 3.11 Coronary artery flow with increased resistance indicated by the arrows [13] 
The results from Figures 3.10 and 3.11 indicate the importance of coronary stenosis 
and its effect on total CBF. For the present study, an addition of coronary stenosis 
(increased RCOR), or impeding the coronary artery in any way, would result in highly 
negative effects on the total CBF and thus myocardial oxygenation. This highlights the 
sensitivity of the coronary circulation to any change in the local resistance of the aortic 
arch and the importance of including it in the Norwood in vitro model.  
Discussion 
The verification study has shown that the in vitro MCS accurately reproduces the 
results predicted by the analytical model when tuned to similar conditions. Specifically, 
the in vitro coronary circulation produces physiological results for varying ranges of 
RCOR and changes in CCB, indicating the versatility of the SVP-CCB coupling chamber. 
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Once it was established that the MCS was a capable model, it was then necessary to 
validate the model.  A patient-specific study was used for this purpose.  
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CHAPTER FOUR 
VALIDATION OF THE IN VITRO MODEL 
The System Setup 
In order to validate the MCS, it must be able to reproduce clinical data pertaining to a 
patient-specific setup (a LPN tuned to patient-specific impedance with an appropriate 
input aortic pressure waveform). This patient-specific study is necessary to ensure the 
MCS models physiological hemodynamics from which clinical implications can be 
obtained. And so, data from a HLHS patient (MUSC2) who received a 3.5mm diameter 
mBTS in the Norwood surgery was used for validation. A test section (Figure 4.1) was 
made based on medical imaging data of the blood volumes to incorporate the patient-
specific structural characteristics of the reconstructed aortic arch.  
 
Figure 4.1 The MUSC2 3-D printed test section: (A) Descending Aorta, (B) LCA, (C) Innominate 
artery, (D) mBTS, (E) Coronary artery 
 
Figure 4.1 shows the 3-D printed MUSC2 test section of the reconstructed aortic arch. 
Similar to the model used in the verification study, a representative coronary artery (2 
mm inner diameter) was placed at the site of the DKS anastomosis (Figure 4.1 E). Any 
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flow towards the DKS was assumed to go to the coronary circulation, similar to the 
assumption by Corsini et al. [43]. Additionally, the MUSC2 model does not have an 
LSA, which was disconnected during Stage 1 surgery. However, it is common for the 
body to adjust for this change by creating connections at more distal points within the 
vasculature [22]. And so, the resistance and compliance of the LSA was incorporated into 
the LCA, resulting in the LPN of the MCS seen in Figure 4.2.  
 
Figure 4.2 Schematic of the MCS used for the MUSC2 validation study. 
 
The clinical data provides flow estimates for the cardiac output, upper body, lower 
body, and mBTS/pulmonary. However, because coronary flow is not typically measured 
in vivo during Stage 1 surgery, the flow had to be estimated. It was previously stated that 
coronary flow is approximately 4% of the cardiac output [15]. This would result in 
0.0504 Lpm for the MUSC2 QCOR. Additionally, Duncker et al. showed that QCOR per 
gram of myocardium [mL/min-g] could be related to heart rate (HR) [bpm] using 
Equation 4.1 [16]. 
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!!"#!"#$%&'()* !"#$!!  = 0.016 ∗ 𝐻𝑅 −  0.30      (4.1) 
Rastin et al. also proposed that myocardium weight could be estimated based on 
patient weight [44]. The MUSC2 patient had a weight of 5.4 Kg and so the estimated 
myocardium weight was 30 g. Together with the heart rate of 120 bpm, the CBF was 
calculated using Eq. 4.1 to be 0.486 Lpm. This value was approximately 3.9% of the 
cardiac output for MUSC2. Based on the two methods of estimating CBF, an average of 
the two results was taken, resulting in target QCOR of 0.050 Lpm for MUSC2. To account 
for this flow in the cardiac output and satisfy continuity, the estimated QCOR was 
subtracted from QUB and QLB equally. This was done because clinical data of cardiac 
output and mBTS flow waveforms were to be matched in the validation study, whereas 
upper and lower body flows were not. Adding or subtracting QCOR from the mean QAO 
and QmBTS would have tainted the validation efforts, as well as change the target clinical 
QP/QS. 
The MUSC2 model has a BSA of 0.30 m2. The LPN values for the coronary 
circulation (Appendix B) were scaled according to the methods proposed by Pennati and 
Fumero [40]. The coronary resistance values and the estimated QCOR were then used to 
estimate the mean pressures PCA1, PCA2, and PCB. The SVP minimum and maximum 
pressures were adjusted based on the clinical mean atrium pressure and maximum clinical 
systolic aortic pressure. Systolic time for the SVP was based on the notion that 
ventricular pressure rises slightly before aortic pressure during isovolumetric contraction. 
Additionally, the descent of the SVP was adjusted to cross the dichrotic notch of the 
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clinical PAO. This completed the parameters necessary for setting up the MUSC2 coronary 
circulation. 
To account for the viscous effects of blood in the test section, a glycerin solution 
(58% water and 42% glycerin) was used as a blood analog. This mixture resulted in a 
density of 1096 kg/m3, a kinematic viscosity of 3.85 cS, and a dynamic viscosity of 4.21 
cP. These values fell within clinical ranges for blood and those used by the in silico 
Norwood studies [9, 10]. Additionally, the heart rate was 120 bpm, resulting in a 0.50 
second cardiac cycle. All flow and pressure measurements were measured using the same 
equipment and methods from the verification study (see Appendix A). The MUSC2 pre-
Glenn catheterization and echo data were used to match aortic pressure, cardiac output, 
and mBTS flow waveforms. Results were analyzed using the same methods proposed in 
the verification study (See Appendix C for details). 
Validation Results 
The results of the MUSC2 validation study can be seen in Tables 4.1 and 4.2. 
Statistically significant differences (p<0.05) are considered clinically insignificant if they 
met the following criteria: mean pressure was within 1 mmHg of in vivo measurement or 
if the mean flow’s uncertainty encompassed the clinical value. This was assumed because 
in vivo flow uncertainty is unknown but usually taken to be within 10%, and pressure 
measurement resolution is 1 mmHg. 
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Table 4.1 Mean results of the MCS validation test compared against mean clinical values.  and the 
estimated mean coronary values. MCS values = mean ± uncertainty  
Flow [Lpm] Clinical MCS Resistance [WU] Clinical MCS 
Cardiac Output (QAO) 1.26 1.25 ± 0.01 Upper Body (UBSVR) 170 175 ± 6 
Upper Body  (QUB) 0.31 0.30 ± 0.01 Lower Body (LBSVR) 166 169 ± 6 
Lower Body (QLB) 0.32 0.31 ± 0.01 mBTS (RmBTS ) 80 79 ± 1 
Pulmonary (QmBTS) 0.58 0.58 ± 0.01 Pulmonary (Rpul) 10 11 ± 0.2 
Pressure [mm Hg] Clinical MCS Pressure [mm Hg] Clinical MCS 
Ascending Aorta  (PAO) 58.76 58.99 ± 0.30 Pulmonary (Ppul) 12.00 12.61 ± 0.06 
 
Table 4.2 Mean results of the MCS validation test compared against the estimated mean coronary 
values. MCS values = mean ± uncertainty  
Flow [Lpm] Estimated MCS 
Coronary (QCOR) 0.050 0.049 ± 0.002 
Pressure [mm Hg] Estimated MCS 
Coronary CA1 (PCA1) 52.33 51.86 ± 0.26 
Coronary CA2 (PCA2) 42.55 41.86 ± 0.21 
Coronary CB (PCB) 32.77 30.39 ± 0.15 
Resistance [WU] Estimated MCS 
Coronary Artery (RCOR) 129 144 ± 6 
Coronary CA1 (RCA1) 196 203 ± 8 
Coronary CA2 (RCA2) 196 232 ± 10 
Coronary CB (RCB) 535 494 ± 20 
Total Coronary (RTC) 1055 1073 ± 44 
 
From Tables 4.1 and 4.2, the mean results are in good agreement and differences 
considered insignificant based on the stated criteria. For instance, the cardiac output 
(QAO) was found to have statistical difference in means (p<0.05), however the uncertainty 
of the MCS value included the clinical reference value. Additionally, the QAO clinical and 
MCS waveforms were reasonably correlated (R2=0.91, σ=9.9%). The QmBTS waveforms 
were also highly correlated (R2=0.96, σ=13.5%) and found to have no statistical 
difference in means (p=0.15). These flow waveforms are seen in Figure 4.3. 
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Figure 4.3 Clinical and MCS aortic flow (R2=0.91, σ=9.9%) and mBTS flow (R2=0.96, σ=13.5%) 
The MCS and clinical aortic pressure waveforms (Figure 4.4) also reveal high 
correlation (R2=0.97, σ=6.0%). Mean PAO results did reveal statistical differences 
(p<0.05), however the MCS value was within 1 mmHg of the clinical. Additionally, the 
clinical and MCS aortic pulse pressures are 64.8 mmHg and 66.5 mmHg, respectively. 
For the systolic portion of PAO, the clinical dP/dt is 838 mmHg/s and the MCS dP/dt is 
824 mmHg/s.  
 
Figure 4.4 Clinical and MCS aortic pressure waveforms (R2=0.97, σ=6.0%) 
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The proximal compliance (CProx) is used to provide compliance to the rigid test 
section, and thus shape the aortic pressure waveform. The MSC CProx was measured to be 
0.082 mL/mmHg. While there are no clinical compliance values available, scaling CProx 
from the verification model would result in a value of 0.084 mL/mmHg. The similarity of 
these values is noteworthy considering that the verification test section was derived from 
the MUSC2 patient [10]. The additional MCS compliance values are seen in Table 4.3 
where they are compared to the scaled compliance values of the verification LPN. CCB 
scaled to a value of 0.0068 mL/mmHg, compared to the verification model’s CCB of 
0.0078 mL/mmHg. The difference in values was determined to be indistinguishable 
between different CCB materials and so the same 0.040-inch thick latex rubber was used 
for CCB. 
Table 4.3 Experimental compliance values of the validation study relative to scaled values from the 
verification model. Compliance (C) [mL/mmHg] 
 CProx CPul CLB CInom 
MCS  0.082 ± .006 0.29 ± .08 0.081± .009 0.117± .011 
BSA Scaled  0.084 0.34 0.069 0.078 
 CLCA CCA1 CCA2  
MCS  0.115 ± .008 0.00025 ± 0.00012 0.00050 ± 0.00013  
BSA Scaled  0.078 0.00017 0.00046  
 
As shown in Table 4.3, there are notable similarities in the validation MCS’s 
compliance values and those estimated by the analytical model from the verification 
study. This, along with the Table 4.1 results and the highly correlated waveforms, 
supports the notion that the MCS is validated against clinical data. Additionally, the MCS 
QCOR (Table 4.2) was found to have no statistical difference (p=0.51) from the estimated 
QCOR. The resistances (Table 4.2) through the coronary circulation were well matched, 
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resulting in coronary pressures consistent with the predicted values. Lastly, the QCOR 
waveform displayed the same coronary flow characteristics that were expected. These are 
seen in Figure 4.5 with respect to the aortic pressure and the arterial coronary pressure, 
PCA1.  
 
Figure 4.5 The QCOR waveform (Right axis) in relation to PAO and PCA1 waveforms (Left axis). 
 
In Figure 4.5, QCOR during early systole displays a slight retrograde flow. As shown 
by PCA1, this is caused by the increase in intramyocardial pressure during the 
isovolumetric contraction of the cardiac cycle. In the isovolumetric time period there is 
no cardiac output and the aortic pressure is low. Once the aortic flow starts, the aortic 
pressure rises and offsets the coronary perfusion pressure to allow for an increase in 
QCOR. However, it isn’t until diastole that the intramyocardial pressure drops and PCA1 
falls substantially. This difference in PCA1 and PAO allows for the sharp increase in QCOR. 
Consequently, the QCOR waveform for the validation case is physiologically accurate. 
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Discussion 
The clinical reference data was recapitulated by the in vitro MCS, all while 
incorporating an in vitro coronary system that produced physiological results. It can 
therefore be concluded that the MCS is a validated system. However, with regards to how 
the coronary system is performing, a single validation case cannot define clinical 
implications. The CBF was purely estimated and can only be used as a reference point. 
To obtain meaningful relationships between the coronary flow and the rest of the MCS, a 
parametric study must be performed.  
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CHAPTER FIVE 
MBTS PARAMETRIC STUDY 
Purpose 
The Norwood procedure using the mBTS is notorious for its negative effects on 
coronary perfusion. In silico studies [8–11] have explicitly related mBTS size to coronary 
perfusion pressure, flow, and the overall balance of pulmonary and systemic flow 
(QP/QS), factors crucial to a Norwood patient’s survival. As previously mentioned, no in 
vitro model has studied this relationship, which brings about the purpose of this 
parametric study. By obtaining in vitro results for the effects of changing mBTS size on 
coronary hemodynamics, the results can confirm or negate those presented by the in 
silico models. These results, regardless of the agreement, can then be used for clinical 
implications. 
Testing Methods 
The inner diameter of the mBTS was used as the varying parameter in this study. The 
MUSC2 patient-specific test section and setup from the validation study (Figure 4.2) was 
used as the reference case from which mBTS changes were made. As the reference 
MUSC2 test section had a 3.5mm mBTS, two other models were created with a 3mm 
mBTS and 4mm mBTS. These values are the typical sizes used in studies evaluating 
mBTS size effects, and so they were used here for comparison to such studies [8–11]. It 
is also important to note that because the validated MCS of a 3.5 mm mBTS patient used 
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estimated coronary hemodynamics, the parametric study’s coronary results should only 
be viewed relative to the 3.5 mm mBTS results.  
The initial test was using the 3.5mm mBTS, and was essentially another validation 
case. Then the test section would be interchanged with another of a different mBTS size. 
The resistance, compliance, and atrium pressure of the 3.5mm test setup were held 
constant throughout all test section changes. For the 3mm and 4mm mBTS models, the 
first two cases studied were maintaining the mean aortic pressure and maintaining the 
cardiac output of the 3.5mm mBTS case. By maintaining the aortic pressure and thus 
upper body flow, this simulated the idea of constant cerebral perfusion (maintaining the 
original blood flow to the brain). Any changes in aortic pressure were also adjusted-for in 
the SVP: if peak systolic PAO increased/decreased, then SVP would increase/decrease 
accordingly.  
Under the same testing conditions, an additional study looked at maintaining the ratio 
VP/CBF for all shunt sizes. This ratio (Equation 5.1) relates the ventricle power output 
(VP) to the supply of coronary blood (CBF).  
𝑉𝑃/𝐶𝐵𝐹 =  !!! 𝑃!"𝑄!"(𝑡)𝑑𝑡 !!! /𝑄𝐶𝑂𝑅      (5.1) 
where tc is the time for one cardiac cycle, 𝑃!"𝑄!"(𝑡) is the ensembled product of PAO 
and QAO at each point in the cardiac cycle, and QCOR is the mean CBF. 
The Norwood heart has limited myocardial oxygen reserve [12], meaning that there 
isn’t much ability for the myocardium to extract more oxygen for the same amount of 
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coronary blood provided. CBF provides the oxygen to the heart so that it can contract and 
produce work. By maintaining the ratio of power output for a given amount of CBF, this 
simulates the heart not working more or less for the amount of “energy” provided.   
All testing for each shunt model was performed during the same testing session to 
ensure consistency between the tuned system parameters and VAD. The same system 
tuning and data recording methods as the verification and validation studies were used in 
the parametric study (Appendix A). Results were analyzed using the previously stated 
methods for the verification and validation studies (Appendix C).  
Results for Constant Cardiac Output 
Table 5.1 presents the results from the 3.5 mm mBTS setup. It was important to 
obtain clinical validation of the MCS results before comparing to the 3 mm and 4 mm 
mBTS results. In doing so, changes using the different sized shunts would be relative to 
clinical values.   
Table 5.1 Results for the 3.5mm mBTS system setup. MCS = Mean ± Uncertainty 
Flow [Lpm] Clinical MCS Flow [Lpm] Estimated MCS 
Cardiac Output (QAO) 1.26 1.27 ± 0.01 Coronary (QCOR) 0.050 0.051 ± 0.002 
Upper Body  (QUB) 0.31 0.31 ± 0.01 Pressure [mmHg] Estimated MCS 
Lower Body (QLB) 0.32 0.32 ± 0.01 Coronary CA1 (PCA1) 52.33 52.83 ± 0.26 
Pulmonary (QmBTS) 0.58 0.58 ± 0.01 Coronary CA2 (PCA2) 42.55 43.04 ± 0.21 
Pressure [mm Hg] Clinical MCS Coronary CB (PCB) 32.77 32.28 ± 0.15 
Ascending Aorta  (PAO) 58.76 58.63 ± 0.30 Resistance [WU] Estimated MCS 
Pulmonary (Ppul) 12 11.96 ± 0.06 Coronary Artery (RCOR) 129 114 ± 4 
Atrium (PAtr) 6 6.02 ± 0.06 Coronary CA1 (RCA1) 196 193 ± 8 
Resistance [WU] Clinical MCS Coronary CA2 (RCA2) 196 212 ± 8 
Upper Body (UBSVR) 170.2 169 ± 5 Coronary CB (RCB) 535 517 ± 20 
Lower Body (LBSVR) 165.9 164 ± 5 Total Coronary (RTC) 1055 1055 ± 41 
mBTS (RmBTS ) 80.1 80 ± 1    
Pulmonary (Rpul) 10 10 ± 0.2    
81 
 
 
The mean results of Table 5.1 are in good agreement with the clinical and estimated 
values, illustrating the MCS’s repeatability. No clinical significance in data was detected. 
The PAO clinical and MCS waveforms were reasonably fitted (R2=0.90, σ=11.7%). The 
QAO waveforms were well matched (R2=0.97, σ=7.3%), as were the QmBTS waveforms 
(R2=0.95, σ=9.7%). These are seen in Figure 5.1.  
  
Figure 5.1 Parametric study validation waveforms of QAO, QmBTS, and PAO. 
Once it was established that the MCS was working under the correct clinical 
conditions, the test sections were interchanged. Cardiac output was maintained by 
adjusting the aortic pressure using the VAD and the resulting hemodynamics were 
recorded (Table 5.2). 
Table 5.2 Parametric study results for constant cardiac output. Mean results for flow [Lpm] and 
pressure [mmHg]. (Bottom three rows) Percent change relative to the 3.5mm values. 
mBTS QCOR QmBTS QUB QLB QP / QS PAO 
3 mm 0.053 ± 0.002 0.56 ± 0.01 0.33 ± 0.01 0.33 ± 0.01 0.79 61.8 ± 0.3 
3.5 mm 0.051 ± 0.002 0.58 ± 0.01 0.31 ± 0.01 0.32 ± 0.01 0.85 58.6 ± 0.3 
4 mm 0.048 ± 0.002 0.61 ± 0.01 0.30 ± 0.01 0.31 ± 0.01 0.92 55.2 ± 0.3 
mBTS QCOR QmBTS QUB QLB QP / QS PAO 
3 mm 5% -4% 3% 3% -7% 5% 
3.5 mm - - - - - - 
4 mm -6% 4% -3% -3% 8% -6% 
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From Table 5.2, increasing the mBTS from a 3mm to a 4mm size and maintaining the 
cardiac output required a large decrease in the mean PAO to account for the decreased 
total MCS resistance. Further, as shunt size increased, the QmBTS also increased while the 
systemic circulation suffered. This is shown individually through the decreased QUB, QLB, 
and QCOR, with the total effect shown by the large increase in QP/QS.  
Additionally, all mean values of Table 5.2 were found to have significant difference 
(p<0.05) between the different mBTS sizes. The most notable difference is seen in the 
percent change of coronary flow. The variation in mBTS caused a span of 11% change 
(from 3mm to 4mm) in QCOR. This disparity can better be seen in Figure 5.2 of the aortic 
pressure, coronary flow, and mBTS flow waveforms.  
 
Figure 5.2 Waveforms for PAO, QmBTS, and QCOR for the varying shunt sizes while held at 
constant cardiac output. 
Figure 5.2 shows that as the mBTS size increased, the systolic and diastolic QmBTS 
increased. To maintain the cardiac output, the peak systolic PAO decreased while also 
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decreasing the diastolic aortic pressure. Because the systolic PAO decreased, the SVP also 
decreased its peak systolic pressure. Therefore, the difference in QCOR is not as evident 
during systole. However, in diastole, because the diastolic aortic pressure decreased with 
increased mBTS size, the diastolic QCOR also decreased due to the reduced perfusion 
pressure, CPP. Seeing as QmBTS increased in the diastolic time period while QCOR 
decreased, this indicates the “shunt stealing” [9] phenomenon.  
Results for Constant Aortic Pressure 
In a similar manner to the constant cardiac output study, results were obtained for the 
different mBTS sizes while maintaining the mean aortic pressure. These results can be 
seen in Table 5.3. 
Table 5.3 Parametric study results for constant aortic pressure. Mean results for flow [Lpm] and 
pressure [mmHg]. (Bottom three rows) Percent change relative to the 3.5mm values. 
mBTS QCOR QmBTS QUB QLB QAO QP / QS 
3 mm 0.051 ± 0.002 0.54 ± 0.01 0.31 ± 0.01 0.32 ± 0.01 1.22 ± 0.01 0.79 
3.5 mm 0.051 ± 0.002 0.58 ± 0.01 0.31 ± 0.01 0.32 ± 0.01 1.27 ± 0.01 0.85 
4 mm 0.050 ± 0.002 0.63 ± 0.01 0.32 ± 0.01 0.32 ± 0.01 1.32 ± 0.01 0.91 
mBTS QCOR QmBTS QUB QLB QAO QP / QS 
3 mm 0% -7% 0% 0% -4% -7% 
3.5 mm - - - - - - 
4 mm -1% 9% 1% 0% 4% 8% 
 
The mean results of maintaining aortic pressure (Table 5.3) are not as dramatic as 
those of maintaining cardiac output (Table 5.2). As the MCS’s resistance, except for the 
shunt, stayed the same with each varying mBTS test section, maintaining aortic pressure 
should result in no change in the mean flows to each region where resistance didn’t 
change. Thus, the systemic flow results do not reveal any noteworthy differences. The 
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only notable changes are with QAO, QmBTS, and QP/QS. In fact, when maintaining aortic 
pressure, the relative change in QmBTS is much more noticeable. However, comparing the 
QP/QS of Table 5.2 and Table 5.3, the same relative changes were achieved. This reveals 
that regardless of whether the heart works to maintain cardiac output or aortic pressure, 
the Qp/QS is highly sensitive to the mBTS size.  
Results for Constant Ventricle Power per Coronary Flow 
The results of maintaining the VP/CBF are seen in Table 5.4. The results of VP and 
VP/CBF are also shown for the other cases. Note that VP/CBF for the constant cardiac 
output case of the 3mm mBTS resulted in the same VP/CBF ratio as the 3.5mm mBTS. 
Table 5.4 Parametric study results for constant SVP/CBF [J/L]. Mean flow (Q) [Lpm], Mean 
pressure (P) [mmHg], Ventricle Power (VP) [mW]. Test results from the constant QAO and mean PAO 
cases are denoted by “CO” and “P”, respectively. A * is used to denote constant VP/SVP (Bottom 
three rows) Percent change relative to the 3.5mm values. 
mBTS QCOR QAO PAO QmBTS QP/QS VP VP/CBF 
3 mm P 0.051 ± 0.002 1.22 ± 0.01 58.8 ± 0.3 0.54 ± 0.01 0.79 187.1 220.2 
3 mm CO * 0.053 ± 0.002 1.27 ± 0.01 61.8 ± 0.3 0.56 ± 0.01 0.79 205.3 231.3 
3.5 mm 0.051 ± 0.002 1.27 ± 0.01 58.6 ± 0.3 0.58 ± 0.01 0.85 196.3 231.9 
4 mm * 0.047 ± 0.002 1.25 ± 0.01 53.9 ± 0.3 0.60 ± 0.01 0.92 180.2 231.9 
4 mm CO 0.048 ± 0.002 1.27 ± 0.01 55.2 ± 0.3 0.61 ± 0.01 0.92 187.7 236.7 
4 mm P 0.050 ± 0.002 1.32 ± 0.01 58.8 ± 0.3 0.63 ± 0.01 0.91 208.7 250.3 
mBTS QCOR QAO PAO QmBTS QP/QS VP VP/CBF 
3 mm P 0% -4% 0% -7% -7% -5% -5% 
3 mm CO * 5% 0% 5% -4% -7% 5% 0% 
3.5 mm - - - - - - - 
4 mm * -8% -2% -8% 3% 8% -8% 0% 
4 mm CO -6% 0% -6% 4% 8% -4% 2% 
4 mm P -1% 4% 0% 9% 8% 6% 8% 
 
From Table 5.4, when maintaining VP/CBF and decreasing the shunt size to 3mm, 
there is a 5% increase in CBF and ventricle power. However, there is a 7% decrease in 
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QP/QS, which would result in a less oxygen saturation rates for the CBF. The combination 
of decreased saturation rates and increased power are unfavorable for the single ventricle 
heart. Likewise, when the mBTS is increased to 4mm, there is an 8% loss of CBF with an 
8% decrease in VP. This also results in a drop (2% decrease) in cardiac output. Lower 
QAO coupled with the increased (8%) QP/QS results in a drop in systemic blood flow, 
which may be problematic for cerebral perfusion.  
Lastly, consider if the heart were to attempt to increase CBF to the initial 3.5mm case 
value, as in the “4 mm P” scenario. The heart would then have to increase VP by 6%, 
resulting in an increase of the ratio VP/CBF by 8%. As the myocardium has limited 
oxygen extraction reserve [12], it is likely unrealistic to consider this situation where the 
heart would work harder for the same amount of CBF provided.  
Discussion and Clinical Implications 
The results of this in vitro study reveal that as shunt size (the inner diameter of the 
mBTS) increases in a Norwood patient, the blood flow to the myocardium (CBF) 
decreases. Figure 5.2 shows that CBF and diastolic PAO decrease with increasing mBTS 
size. CBF is dependent on the CPP, as well as the ventricular contraction’s interaction 
with the coronary vasculature [18]. In this study, changes in the ventricular contraction 
are accounted for using the SVP-CCB coupling chamber by adjusting the SVP. That is 
why Figure 5.2 did not reveal a substantial difference in CBF during systole; as systolic 
PAO increased so did SVP. The real difference was in diastole where ventricular 
contraction (and so SVP) has its least restraining effect on CBF, and CPP is the main 
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dictator of how much QCOR there is. Thus, because diastolic PAO decreases with 
increasing mBTS size, CPP decreases and there is less QCOR.  
Table 5.4 shows that as mBTS size increases the ratio of pulmonary to systemic blood 
flow (QP/Qs) also increases. While this may lead to a better balance of oxygenated and 
deoxygenated blood in the Norwood patient, the myocardium is still receiving less blood 
flow, particularly in the 4mm case of constant VP/CBF. The myocardium’s oxygen 
extraction capabilities are limited [21]. So, in the condition that the heart would either 
maintain a certain amount of cardiac output or maintain the VP/CBF after Norwood 
palliation, a shunt too large in size would result in a relatively lower CBF.  
In order to increase the CBF with the larger shunt, issues arise with the systolic PAO 
and required ventricle power. This idea was shown through the constant aortic pressure 
tests where coronary blood flow was maintained for the various mBTS sizes. While mean 
PAO is the same between all shunt sizes, the aortic pressure waveforms reveal that systolic 
pressure increases and diastolic pressure slightly decreases with increasing shunt size. 
This can be seen in Figure 5.3 of PAO for various shunt sizes at a constant mean PAO. 
  
Figure 5.3 Waveforms for PAO for the varying shunt sizes while maintaining the average PAO. 
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In maintaining mean PAO and CBF, Figure 5.3 reveals the change in shunt size, and 
thus impedance of the circulation, changes the form of PAO. The systolic PAO and SVP 
increase with the larger mBTS. The increased SVP increases myocardial work and 
oxygen demand [21]. This idea is also shown through the 6% increase in ventricle power 
and 8% in VP/CBF from Table 5.5. So in the case where the heart attempted to maintain 
a certain cardiac output there was less CBF. If the heart were to increase the CBF, then 
the results reveal that the systolic peak, cardiac output, and thus power output would have 
to increase. This idea is also illustrated with Figure 5.4. 
 
Figure 5.4 Waveforms for PAO and QCOR for the reference 3.5mm shunt size and the 4 mm shunt 
size. Labels with “PAO” are from the constant aortic pressure test and labels with “CO” are from the 
constant cardiac output test. 
Figure 5.4 shows that when the mBTS size was increased, CBF and PAO decreased for 
the constant cardiac output case. When PAO was increased to achieve the same CBF as 
the 3.5 mm mBTS case, the systolic PAO increased (“4 mm PAO PAO” in Fig. 5.4). From 
Table 5.4, the 4mm mBTS with constant mean aortic pressure had a 6% increase in VP 
and 8% increase in VP/CBF. This means that the heart would be working harder and 
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demanding more oxygen for essentially the same amount of CBF as the 3.5 mm case. 
This could result in a devastating cyclic reaction where the heart continues to work harder 
to increase CBF but isn’t able to supply enough oxygen to the myocardium for the 
amount of work performed. As the Norwood heart is already a single ventricle system 
having undergone highly invasive modifications, it is advised that caution is given to how 
mBTS size can affect CBF and ventricular function.  
In silico studies [7–9, 11] have expressed the detrimental effects of the mBTS on 
Norwood hemodynamics, in particular to coronary perfusion. Specifically, Table 5.5 
shows that as mBTS size increases, coronary blood flow decreases and Qp/QS increases.  
Table 5.5 In silico [7], [9], [11] and in vitro MCS results of varying mBTS size. Top three rows: Flow 
(Q) [Lpm] and pressure (P) [mmHg]. Bottom three rows: Changes relative to the 3.5mm results. 
Bove et al. [7] Moghadam et al. [9] 
mBTS  QAO PAO QCOR QP/QS mBTS  QAO PAO QCOR QP/QS 
3 mm 2.12   0.081 0.72 3 mm 2.09   0.0854 0.726 
3.5 mm 2.28   0.076 1 3.5 mm 2.23   0.0796 1.004 
4 mm 2.38   0.071 1.26 4 mm 2.35   0.0741 1.302 
  QAO PAO QCOR QP/QS   QAO PAO QCOR QP/QS 
3 mm -7%   7% -28% 3 mm -6%   7% -28% 
3.5 mm -  - - - 3.5 mm -  - - - 
4 mm 4%   -7% 26% 4 mm 5%   -7% 30% 
Lagana et al. [11] in vitro MCS 
mBTS  QAO PAO QCOR QP/QS mBTS  QAO PAO QCOR QP/QS 
3 mm 2.123 84.56 0.082 0.72 3 mm 1.27 61.76 0.053 0.79 
3.5 mm 2.275 79.83 0.076 1.003 3.5 mm 1.27 58.63 0.051 0.85 
4 mm 2.387 75.67 0.071 1.254 4 mm 1.27 55.17 0.048 0.92 
  QAO PAO QCOR QP/QS   QAO PAO QCOR QP/QS 
3 mm -7% 6% 8% -28% 3 mm 0% 5% 5% -7% 
3.5 mm -  - - - 3.5 mm -  - - - 
4 mm 5% -5% -7% 25% 4 mm 0% -6% -6% 8% 
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These in silico results of Table 5.5 are consistent with the in vitro findings in the 
present study, which reveals two important conclusions. The first is that since the in silico 
results agree with the in vitro results, the in silico results are verified and can be used for 
clinical implications. The second is that both results reveal the negative effects of 
increasing mBTS size, which could lead to the demise of the Norwood heart.  
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CHAPTER SIX 
CONCLUSION 
Conclusion 
In completing this study, the objectives were evaluated for their level of 
completeness, and the hypothesis analyzed as either accepted or rejected. The objectives 
(1-5) and hypothesis (6) are re-stated here: 
1. Design and integrate a coronary circulation into a previously validated in vitro 
multi-scale model [28]   
2. Verify the system’s response against a mathematical model 
3. Validate the in vitro coronary blood flow against clinical findings in literature 
4. Validate the entire in vitro model against clinical data of a HLHS patient 
5. Investigate the effects of mBTS size on coronary perfusion  
6. The in vitro model will illustrate how increased mBTS size negatively affects 
coronary perfusion  
The present study conducted tests on a mock circulatory system of the Norwood with 
mBTS palliation. The MCS featured the pulmonary and systemic circulations from the 
Hang  [28]  MCS. The history of coronary modeling was investigated and led to the 
design of an in vitro coronary circulation that was implemented into the MCS, 
completing objective #1. A mathematical model and clinical-based literature references 
on CBF were used to verify the workings of the MCS and validate the coronary model, 
completing objectives #2 and #3. A patient-specific test (MUSC2) was used to validate 
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the MCS, completing objective #4. A patient-specific study that analyzed the effects of 
mBTS size on the Norwood, and specifically coronary, hemodynamics was conducted, 
completing objective #5. Thus, all five objectives were met. 
In the mBTS parametric study, it was shown (see Figure 5.2) how increasing mBTS 
size decreases the diastolic aortic pressure. The diastolic aortic pressure is part of the 
coronary perfusion pressure, and so a decrease in diastolic PAO leads to a decrease in 
coronary blood flow. Thus, a direct link between mBTS size and coronary perfusion was 
found, and the result was that increased mBTS size does negatively affect (by decreasing) 
the CBF. And so, the hypothesis is accepted. 
Advantages, Disadvantages, and Future Work 
The CBF was not validated against exact Norwood clinical data, but rather the best 
insight as to what Norwood coronary hemodynamics would be. However, in the event 
that clinical Norwood coronary data is obtained, the system could be operated to reflect 
such data. Additionally, the MCS is an open-loop system; there is no feedback to the 
VAD or RC components when applying distressing changes like increased mBTS size. 
Aortic pressure or flow is held constant in these cases to best approximate how the 
human body might respond. The in vitro MCS could be improved by adding 
autoregulation using a feedback-controlled system. The system could be integrated into 
the control of the VAD based on the flow and pressure in vitro measurements.   
The MCS presented in this study is advantageous in that it is the first validated in 
vitro system of the Norwood palliation to feature the coronary circulation. It allowed for 
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verification of previous in silico studies through the mBTS parametric study. It can now 
be used to investigate other variables that would affect Norwood coronary 
hemodynamics, such as coarctation. Additionally, medical devices can be tested on this 
platform to see their effect on CBF. For instance, DeCampli et al. evaluated the use of a 
“counter-pulsation” device on the mBTS to improve coronary perfusion in neonatal pigs 
[45]. To test this device on human Norwood hemodynamics, the device could be 
implemented in the in vitro MCS. Comparison between the results obtained with and 
without the device would reveal its effectiveness. Hence, the presented and potential 
work of the in vitro MCS highlights the importance of an experimental setup in 
continuing engineering breakthroughs for single ventricle palliations.  
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APPENDIX A: EQUIPMENT AND SYSTEM CALIBRATION  
Table A.1 lists all equipment used to create the MCS and for measurement taking. 
Table A.1 Equipment used in in vivo MCS setup and data recording. 
 Equipment Purpose 
M
C
S 
Clear PVC pipe Compliance air chambers. Sized as needed 
Pinch-needle valves Resistance elements 
Silicone rubber clear tubing 
Connections between resistance, 
compliance, test section, and VAD. 
Sized as needed. 
Barbed tube fittings Connect tubing to compliance air chambers 
Plastic couplings (straight, T-joint, elbow) Connect LPN tubing 
Type 303 stainless steel hose barb Grounding connection to LPN 
Metal wire 
Grounding connection from SS 
hose barbs to Atrium tank and flow 
meters 
Ventricular-Assist Device  (Excor®, Berlin Heart 25 cc, Berlin, 
Germany) 
 
Create input flow to test section 
during pulsatile flow 
Piezo pressure regulator (Type: PRE-U2, Hoerbiger, Schongau 
Germany) 
Control of vacuum pressure to 
VAD 
3-way valve (Model: 225B-111CAAA, MAC Valve, Dundee, MI, 
USA) 
Alternate high pressure and vacuum 
to VAD and CC. Timing is 
controlled by LabVIEW. 
Pneumatic valve (at least up to10 psi) Control of high pressure to VAD and CC 
Vacuum regulator Control of vacuum to CC 
M
ea
su
re
m
en
ts
 
Electromagnetic probes (P600 series, Carolina Medical Electronics, 
King, NC) (30mm and 15mm circumference) Flow measurements 
Analog Flow Meter (Model FM501, Carolina Medical Electronics, 
King, NC) Flow measurements 
Pressure transducers (BD DTXplus, BD Medical Systems, Sandy, 
UT) Pressure measurements 
Bridge amplifier (Model 2100, Measurements Group Inc., Raleigh, 
NC) 
Pressure measurement’s voltage 
nulling and amplification 
DAQ card (USB NI-6211, National Instruments) and LabVIEW 
software (USB 6211, LabVIEW 8.6; National Instruments, Austin, 
TX) 
Data acquisition from pressure 
transducers and flow meters. 
Sampled at 160 Hz. 
Rigid plastic tubing and pressure taps Connections from LPN to pressure transducers 
Vacuum and compressed air supply VAD control 
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The architecture of the MCS and equipment setup is seen in Figure A.1. 
 
Figure A.1 Schematic of MCS and equipment setup. 
The following is the step-by-step procedure for pressure transducer calibration: 
1. Set the test section’s ascending aorta as the datum height 
2. Set all pressure taps connected to pressure transducers at the datum height 
3. On the pressure transducers, set the black mark at the datum height 
4. Fill a clear beaker with water and set the top of the water at the datum height 
5. Connect a rigid plastic tube from the pressure transducer to the water in the 
beaker, ensuring that water fills the tube completely 
6. With the bridge amplifier turned on and LabVIEW showing the pressure signal, 
adjust the amplifier’s balance until the pressure reading is zero 
7. Apply a known hydrostatic pressure to the beaker and adjust the amplifier’s gain 
until the correct reading is shown on LabVIEW 
8. Repeat for multiple different hydrostatic pressures and all pressure transducers 
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The following is the step-by-step procedure for flow meter calibration: 
1. Turn on flow meter at least 30 minutes prior to use 
2. Ensure all flow probes are filled with a saline solution (30 cc salt/ gallon H2O) 
and there is no movement of the fluid in the probes 
3. Ensure grounding wires from LPN are connected to grounding cables from 
flow meter 
4. Ensure the flow probe’s probe factor is correctly set on the flow meter by 
using the appropriate PFX value and Probe Factor dial 
5. Set the Range dial to the range of flow appropriate to the flow  
6. Turn the Balance dial to 500 
7. With the main dial set on OFF, turn the Zero dial until the analog reading on 
the flow meter is zero 
8. After 30 minutes and with fluid-filled probes, turn the flow meter’s main dial 
to Null and adjust until the analog reading on the flow meter is at its lowest 
value 
9. Turn the main dial to Balance and adjust the Balance dial until the reading on 
LabVIEW is zero 
10. Turn the main dial to + and, if necessary, adjust the Balance dial until the 
reading on LabVIEW is zero 
11. Measurements can now be taken with the dial set to + 
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The following is the step-by-step procedure for tuning the MCS to a desired test setup: 
1. Ensure all flow probes and pressure transducers are calibrated prior to tuning 
2. Adjust compliance air chambers to correct air volumes 
3. Ensure all pressure tubing from pressure transducers to pressure taps in LPN are 
filled with fluid 
4. Using a head tank connected directly to the LPN’s CPROX, set the head tank’s fluid 
height to the hydrostatic pressure of the mean PAO (This is a steady flow setup in 
which the VAD is disconnected and the flow from the Atrium tank is pumped up 
to the head tank) 
5. Adjust resistance valves until the correct flows and pressures are measured in 
each circulation 
6. Once the correct flows and pressures are tuned, disconnect the head tank setup 
and connect the VAD with the VAD’s outflow port going towards CPROX and the 
inflow port connected to the Atrium tank (minimize distance between each 
connection) 
7. Ensure the air pressure connection to the VAD is disconnected and that the 3-way 
valve is turned on and switching back and forth between the compressed air and 
vacuum pressure lines (switching rate determined by systolic-time ratio 
designated in LabVIEW) 
8. Apply compressed air and vacuum pressure to the setup 
9. Slowly connect the air pressure connection to the VAD and track the pressure 
measurement taken between the 3-way valve and VAD. This pressure must not 
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fall outside the range of -80 to 250 mmHg for VAD safety. Adjustments to 
pressure and vacuum regulators will have to be made to apply appropriate 
pressure to VAD and achieve the desired mean aortic flow and pressure. 
10. Get rid of any air bubbles in the MCS tubing 
11. Adjust the MCS’s CPROX to help form the desired PAO and QAO 
12. Adjust the SVP’s air pressure and compressed air to apply the appropriate 
ventricle pressure to the SVP-CCB compliance chamber (CC) 
13. Once the appropriate input PAO is applied to the test section and the appropriate 
SVP applied to the CC, record the resulting pressures and flows using LabVIEW 
Following the previous 13 steps, the following is the step-by-step procedure for 
performing a parametric test in the MCS: 
14. Once the initial setup is tuned and data recorded, disconnect the air pressure from 
the VAD, allowing all flow to stop 
15. Carefully clamp all tubing connections to the test section and remove the test 
section from the MCS 
16. Connect another test section to the MCS. It is critical that the same position the 
previous test section was in is now used for the new test section and that no 
changes to resistance or compliance are made. 
17. Unclamp tubing connections and get rid of any air bubbles 
18. Repeat steps 9-13 for each new test section 
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APPENDIX B: ANALYTICAL MODEL 
A schematic of the verification analytical model is seen in Figure B.1. For the 
analytical model, the inputs were the aortic pressure, aortic flow curve, and the single 
ventricle pressure curve. In Figure B.1, the VAD represents this implementation. 
 
Figure B.1 Schematic of analytical model used for verification. Created by and printed with 
permission of Dr. Tim Conover of Clemson University. 
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Table B.1 shows the LPN values used in the analytical model for the verification study 
and Table B.2 shows the coronary LPN values used in the MUSC2 validation study.   
Table B.1 LPN values used in the analytical model. Pressure (P) [mmHg], Compliance (C) 
[mL/mmHg], Inertance (L) [mmHg.s2/mL], Resistance [mmHg.s/mL] 
Heart Systemic Circulation 
PAtrium 4.1 Linom 0.06919 
CAO 0.095 Rinomp 2.982 
Coronary Circulation Cinom 0.0888 
Lcor 0.02801 Rinomd 14.517 
Rcor 7.01 Llca 0.08783 
Cca1 1.94E-04 Rlcap 2.754 
Rca1 10.6739 Clca 0.0444 
Cca2 5.18E-04 Rlcad 31.399 
Rca2 10.6739 Llsa 0.07724 
Ccb 7.77E-03 Rlsap 2.3541 
Rcb 32.0216 Clsa 0.0444 
Pulmonary Circulation Rlsad 26.8339 
Lshunt 0.04149 Rsvc 0.586 
Rshunt 0.461 Llb 0.02276 
Kshunt 0.14981 Rlbp 0.5097 
CPA 0.3877 Clb 0.0779 
RPA 0.4249 Rlbd 7.8291 
Table B.2 Coronary LPN values for the validation study. Compliance (C) [mL/mmHg], Resistance 
[mmHg.s/mL] 
Coronary Circulation 
Rcor 7.71 
Cca1 1.71E-04 
Rca1 11.7413 
Cca2 4.57E-04 
Rca2 11.7413 
Ccb 6.85E-03 
Rcb 35.2238 
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APPENDIX C: STATISTICS AND UNCERTAINTY ANALYSIS  
Statistics 
The results of all testing were averaged over 10 cardiac cycles worth of data. A t-test 
at 95% confidence was used to compare mean pressure and flow results. Waveforms of 
MCS results and clinical or analytical results were analyzed using the coefficient of 
determination (R2) (Equation C.1).  
𝑅! = ! !!!!"!!!!! !!!!!! !!"!!!!! (!!)!!!!! !( !!!!!! )! ! (!!")!!!!! !( !!"!!!! )!     (C.1) 
In Equation C.1, xi and xci denote the MCS and analytical or clinical value, 
respectively, at the same time point in the cardiac cycle. Additionally, the waveform 
results were analyzed using the normalized root-mean-square error (RMSE).  The 
normalized RMSE was calculated using range (𝑥!"# − 𝑥!"#) and mean values (𝑥) of the 
result. The equations for these are seen in Equations C.2-C.4 
𝑅𝑀𝑆𝐸 = (𝑥! − 𝑥!")!!!!! /𝑁 ∗ 100%      (C.2) 
𝜎 = !"#$!!"#!!!"#         (C.3) 
𝜔 = !"#$!           (C.4) 
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Uncertainty of Pressure and Flow Results 
The uncertainties of mean pressure and mean flow results can be broken into 
systematic and random errors.  Systematic error includes instrument uncertainty, zero-
point error, and DAQ uncertainty. Instrument uncertainty is taken as 0.5% of the reading. 
Zero-point error is the difference between the true zero value and the absolute value of 
the minimum value achieved during zero-ing the equipment during calibration. Previous 
work [28] from this group found the DAQ uncertainty to be ±0.003 Lpm for flow and 
±0.004 mmHg for pressure. Random uncertainty is the standard error which is found 
using Equation C.5. 
 𝑆! = 𝑆!/ 𝑁         (C.5) 
In Equation C.5, the term 𝑆! is the standard deviation and N is the number of mean 
values (or number of cardiac cycles the data was averaged over). The results for this 
thesis were averaged over N=10 cardiac cycles. The total uncertainty of the mean 
variable is then found using Equation C.6 where M stands for the total number of 
uncertainty terms (ui). 
𝑢! = 𝑢!!!!!!          (C.6) 
Examples of pressure and two different flow uncertainty calculations are seen in 
Table C.1. The smaller 15mm circumference flow probe used with the coronary flow 
measurements resulted in less uncertainty compared to the larger 30mm circumference 
103 
 
flow probe used for all other flow measurements. This was due to the smaller values of 
zero-point error, instrument uncertainty, and random uncertainty. 
Table C.1 Example uncertainties for flow and pressure measurements. Flow uncertainty [Lpm], 
Pressure uncertainty [mmHg] 
Name Mean Result 
Instrument 
Uncertainty 
Zero-
Point 
Error 
Data 
Acquisition 
Uncertainty 
Random 
Uncertainty 
Total 
Uncertainty 
Relative 
Value 
QAO 1.7934 0.0090 0.0035 0.003 0.0357 0.037 2% 
QCOR 0.0545 0.0003 0.0004 0.003 0.000641 0.003 6% 
PAO 58.4491 0.2922 0.01 0.004 0.04 0.30 1% 
 
Uncertainty of Resistance and Compliance Results 
The uncertainties of compliance and resistance results are found using the uncertainty 
propagation methods as described by Figliola and Beasley [46]. The propagation of 
uncertainty is found using Equation C.7.   
𝑢! = (!"!!! 𝑢!!)!!!!! !/!        (C.7) 
In Equation C.7, uK is the uncertainty of the result, such as resistance or compliance. 
The term !"!!! is the sensitivity index of each variable, 𝑥!, and 𝑢!! is the uncertainty of the 
variable. For resistance and compliances, such variables were pressure, flow, and air 
volume. 
Resistance is calculated using Equation C.8 and the resulting uncertainty in resistance 
(uR) is calculated using Equation C.9. 
𝑅 = !!!!!!           (C.8) 
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𝑢! = ( !!! 𝑢!!)! + ( !!! 𝑢!!)! + (!!!!!!! 𝑢!)! !/!     (C.9) 
In Equations C.8-C.9, Pu and Pd are the upstream and downstream pressures, 
respectively. The upstream and downstream pressures were measured independently and, 
therefore, had no correlation between their uncertainties.   
The compliance (C) and uncertainty in compliance (uC) are calculated using 
Equations C.10 and C.11.  
𝐶 = !!!"#          (C.10) 
𝑢! = ( !!!!"#! 𝑢!)! + ( !!!"# 𝑢!)! !/!      (C.11) 
In Equation C.10 and C.11, V is the volume of trapped air in the compliance air 
chamber, Pabs is the mean absolute pressure measured at the compliance air chamber. A 
relative value of 1% was used for uncertainty in the volume of trapped air (uv) such that 
100mL of trapped air correlated to 1mL of uncertainty. Pressure uncertainty (up) was 
calculated using Equation C.6. Examples of resistance and compliance uncertainties are 
seen in Tables C.2 and C.3, respectively. 
Table C.2 Example uncertainty for resistance (uR) [mmHg/Lpm] [WU]. 
Resistance PU [mmHg] 𝑢!! [mmHg] PD [mmHg] 𝑢!!  [mmHg] Q [Lpm] 𝑢![Lpm] 𝑢! 
UBSVR 58.6 0.3 6.02 0.06 1.27 0.01 5 
Table C.3 Example uncertainty for compliance (uC) [mL/mmHg]. 
Compliance Pabs [mmHg] 𝑢! [mmHg] V [mL] 𝑢! [mL] 𝑢!  
Cprox 820.4 0.3 77 0.77 0.006 
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APPENDIX D: RESULTS  
Table D.1 Mean flow, mean pressure, resistance, and compliance results for the verification study. 
MCS values = mean ± uncertainty  
Flow [Lpm] Analytical MCS 
Cardiac Output (QAO) 1.82 1.82 ± 0.01 
Upper Body  (QUB) 0.38 0.38 ± 0.01 
Lower Body (QLB) 0.4 0.40 ± 0.01 
Pulmonary (QmBTS) 0.98 0.98 ± 0.01 
Coronary (QCOR) 0.056 0.056 ± 0.002 
Pressure [mm Hg] Analytical MCS 
Ascending Aorta  (PAO) 60.11 60.37 ± 0.30 
Pulmonary (PPul) 11.06 11.05 ± 0.06 
Lower Body (PLB) 56.71 57.56 ± 0.29 
Innominate (Pinom) 51.21 52.34 ± 0.28 
LSA (PLSA) 55.91 49.68 ± 0.28 
LCA (PLCA) 55.91 49.90 ± 0.26 
Coronary CA1 (PCA1) 53.61 57.51 ± 0.28 
Coronary CA2 (PCA2) 43.71 43.89 ± 0.22 
Coronary CB (PCB) 33.8 33.61 ± 0.18 
P atrium 4.1 4.1 ± 0.34 
Resistance [WU] Analytical MCS 
Upper Body (UBSVR) 148 150 ± 4 
Lower Body (LBSVR) 139 140 ± 3 
mBTS (RmBTS ) 50 50 ± 1 
Pulmonary (Rpul) 7 7 ± 0.1 
Total Coronary (RTC) 1000 1005 ± 35 
Coronary Artery (RCOR) 116 51 ± 2 
Coronary CA1 (RCA1) 177 243 ± 9 
Coronary CA2 (RCA2) 177 184 ± 7 
Coronary CB (RCB) 530 527 ± 18 
Compliance [mL/mmHg] Analytical MCS 
CProx 0.095 0.094 ± 0.006 
CPul 0.3877 0.374 ± 0.14 
CLB 0.0779 0.057 ± 0.004 
CInom 0.0888 0.103 ± 0.009 
CLCA 0.0444 0.052 ± 0.005 
CLSA 0.0444 0.052 ± 0.005 
CCA1 0.000194351 0.00024 ± 0.00012 
CCA2 0.000518269 0.00050 ± 0.00013 
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Table D.2 Mean flow, mean pressure, resistance, and compliance results for the coronary verification 
study. MCS values = mean ± uncertainty  
Flow [Lpm] Analytical MCS 
Cardiac Output (QAO) 1.82 1.81 ± 0.01 
Upper Body  (QUB) 0.37 0.37 ± 0.01 
Lower Body (QLB) 0.4 0.40 ± 0.01 
Pulmonary (QmBTS) 0.98 0.98 ± 0.01 
Coronary Artery (QCOR) 0.056 0.057 ± 0.002 
Coronary Vein (QCV) 0.056 0.056 ± 0.005 
Coronary Artery (QCOR + Rcor) 0.05 0.049 ± 0.002 
Coronary Vein (QCV + Rcor) 0.05 0.047 ± 0.005 
Coronary Artery (QCOR ++ Rcor) 0.036 0.035 ± 0.002 
Coronary Vein (QCV ++ Rcor) 0.036 0.032 ± 0.004 
Pressure [mm Hg] Analytical MCS 
Ascending Aorta  (PAO) 60.11 60.65 ± 0.43 
Coronary CA1 (PCA1) 53.63 54.15 ± 0.79 
Coronary CA2 (PCA2) 43.72 43.94 ± 0.39 
Coronary CB (PCB) 33.82 33.53 ± 0.55 
Resistance [WU] Analytical MCS 
Total Coronary (RTC) 1000 993 ± 34 
Coronary Artery (RCOR) 116 111 ± 2 
Coronary CA1 (RCA1) 177 180 ± 7 
Coronary CA2 (RCA2) 177 183 ± 7 
Coronary CB (RCB) 530 518 ± 18 
RCOR + Rcor 232 232 ± 2 
RCOR + + Rcor 691 691 ± 5 
Compliance [mL/mmHg] Analytical MCS 
CCA1 0.000194351 0.00025 ± 0.00012 
CCA2 0.000518269 0.00050 ± 0.00013 
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Table D.3 Mean flow, mean pressure, resistance, and compliance results for the MUSC2 validation 
study. MCS values = mean ± uncertainty  
Flow [Lpm] Clinical MCS 
Cardiac Output (QAO) 1.26 1.25 ± 0.01 
Upper Body  (QUB) 0.31 0.30 ± 0.01 
Lower Body (QLB) 0.32 0.31 ± 0.01 
Pulmonary (QmBTS) 0.58 0.58 ± 0.01 
Coronary (QCOR) 0.05 0.049 ± 0.002 
Pressure [mm Hg] Clinical MCS 
Ascending Aorta  (PAO) 58.76 58.99 ± 0.30 
Pulmonary (PPul) 12 12.61 ± 0.06 
Coronary CA1 (PCA1) 52.33 51.86 ± 0.26 
Coronary CA2 (PCA2) 42.55 41.86 ± 0.21 
Coronary CB (PCB) 32.77 30.39 ± 0.15 
Resistance [WU] Clinical MCS 
Upper Body (UBSVR) 170 175 ± 6 
Lower Body (LBSVR) 166 169 ± 6 
mBTS (RmBTS ) 80 79 ± 1 
Pulmonary (Rpul) 10 11 ± 0.2 
Total Coronary (RTC) 1055 1073 ± 44 
Coronary Artery (RCOR) 129 144 ± 6 
Coronary CA1 (RCA1) 196 203 ± 8 
Coronary CA2 (RCA2) 196 232 ± 10 
Coronary CB (RCB) 535 494 ± 20 
Compliance [mL/mmHg] Analytical MCS 
CProx N/A 0.082 ± .006 
CPul N/A 0.29 ± .08 
CLB N/A 0.081± .009 
CInom N/A 0.117± .011 
CLCA N/A 0.115 ± .008 
CCA1 0.00017 0.00025 ± 0.00012 
CCA2 0.00046 0.00050 ± 0.00013 
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Table D.4 Mean flow, mean pressure, resistance, and compliance results for the MUSC2 mBTS-
parametric study using the 3.5mm mBTS. MCS values = mean ± uncertainty  
Flow [Lpm] Clinical MCS 
Cardiac Output (QAO) 1.26 1.27 ± 0.01 
Upper Body  (QUB) 0.31 0.31 ± 0.01 
Lower Body (QLB) 0.32 0.32 ± 0.01 
Pulmonary (QmBTS) 0.58 0.58 ± 0.01 
Coronary (QCOR) 0.05 0.051 ± 0.002 
Pressure [mm Hg] Clinical MCS 
Ascending Aorta  (PAO) 58.76 58.63 ± 0.30 
Pulmonary (PPul) 12 11.96 ± 0.06 
Atrium (PAtr) 6 6.02 ± 0.06 
Coronary CA1 (PCA1) 52.33 52.83 ± 0.26 
Coronary CA2 (PCA2) 42.55 43.04 ± 0.21 
Coronary CB (PCB) 32.77 32.28 ± 0.15 
Resistance [WU] Clinical MCS 
Upper Body (UBSVR) 170.2 169 ± 5 
Lower Body (LBSVR) 165.9 164 ± 5 
mBTS (RmBTS ) 80.1 80 ± 1 
Pulmonary (Rpul) 10 10 ± 0.2 
Total Coronary (RTC) 1055 1055 ± 41 
Coronary Artery (RCOR) 129 114 ± 4 
Coronary CA1 (RCA1) 196 193 ± 8 
Coronary CA2 (RCA2) 196 212 ± 8 
Coronary CB (RCB) 535 517 ± 20 
Compliance [mL/mmHg] Analytical MCS 
CProx N/A 0.082 ± .006 
CPul N/A 0.29 ± .08 
CLB N/A 0.081± .009 
CInom N/A 0.117± .011 
CLCA N/A 0.115 ± .008 
CCA1 0.00017 0.00025 ± 0.00012 
CCA2 0.00046 0.00050 ± 0.00013 
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Table D.5 Waveform comparison results for all studies: Root-mean-square (RMS), normalized RMS 
(NRMS) by mean and range, and coefficient of determination (R2). 
Verification Study RMS 
NRMS by mean 
(𝜔) NRMS by range (𝜎) R2 
PAO 5.21 8.6% 8.6% 0.92 
QCOR 0.03 52.4% 14.7% 0.83 
QmBTS 0.13 13.2% 41.0% 0.83 
Coronary 
Verification Study RMS 
NRMS by mean 
(𝜔) NRMS by range (𝜎) R2 
PAO 4.957 8.2% 10.2% 0.94 
QCOR 0.025 44.1% 12.6% 0.87 
QCV 0.033 58.8% 15.8% 0.85 
QCOR + R 0.022 44.6% 13.3% 0.87 
QCV + R 0.034 71.5% 16.0% 0.88 
QCOR ++ R 0.011 32.0% 11.0% 0.91 
QCV ++ R 0.030 94.5% 14.2% 0.89 
MUSC2 Validation 
Study RMS 
NRMS by mean 
(𝜔) NRMS by range (𝜎) R2 
PAO 3.98 6.7% 6.0% 0.97 
QmBTS 0.07 11.3% 13.5% 0.97 
QAO 0.48 38.3% 9.9% 0.92 
3.5 mBTS Parametric 
Study Validation RMS 
NRMS by mean 
(𝜔) NRMS by range (𝜎) R2 
PAO 7.02 12.0% 11.7% 0.90 
QmBTS 0.05 7.8% 9.7% 0.98 
QAO 0.41 32.7% 7.3% 0.97 
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